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EXECUTIVE SUMMARY 
 
The ECVAM technical report presents the progress made in the development and validation of 
alternative methods for the human health effects relevant to the Cosmetics Directive. It provides an 
update on the activities described by ECVAM in 20051, 2006 and 20072 
 
The report intends to present the latest scientific and technical developments in the field during 2008-
2009. As required by Directive 2003/15/EC, the seventh amendment to Directive 76/768/EEC, 
developments in refinement and reduction methods are also described (EU, 2003). 
 
The status in 2009 on the development, validation and regulatory acceptance of alternative methods in 
the different human health-related effects of concern to the Cosmetics Directive is as follows: 
  
For acute local effects, such as acute phototoxicity and skin corrosion, validation studies have led to 
the regulatory acceptance of the methods. In the field of skin irritation, the EC had the lead at OECD 
level for a new draft OECD test guideline on In Vitro Skin Irritation: Reconstructed Human Epidermis 
(RhE) Test Method. In parallel, a new EU Test Method B.46 based on the ECVAM-validated 
reconstructed human epidermis assays (EpiSkin™, EpiDerm™ and SkinEthic™RHE) was included in 
the EU Test Method Regulation COM 440/2008. 
For skin penetration, OECD adopted in 2004 a test guideline based on diffusion of chemicals into and 
across skin to a fluid reservoir.  
 
In the area of genotoxicity, the micronucleus test in vitro has been successfully validated in 2006 and 
the draft OECD Test Guideline should soon be adopted, now that new data on the different measures 
of cytotoxicity to be used, while performing the micronucleus test, have been generated by an EU 
working group. Several in vitro genotoxicity tests are in use since decades. However, these tests are 
prone to an unacceptable rate of false positive results, leading to unnecessary follow up animal 
experiments. Following the recommendation of an ECVAM workshop aiming at improving the 
predictivity of the in vitro testing battery, ECVAM has been involved: 1) in the publication of a list of 
chemicals to be used in the evaluation of the performance of new or modified tests and in the analysis 
thereof; and 2) in the analysis of published data for top concentration and upper limit of cytotoxicity 
considerations in mammalian cell genotoxicity testing, which seems to be a reason for false positives. 
Furthermore a prevalidation of the micronucleus test and the comet assay applied to reconstructed 
human skin models is ongoing under the coordination of COLIPA.  
 
In the area of eye irritation, from twelve methods considered as most advanced, ten methods 
underwent validation. In particular, two organotypic assays (the BCOP and the ICE assays), out of the 
four (BCOP, ICE, HET-CAM and IRE) which underwent validation, were endorsed by ESAC in 2007 
as scientifically valid to identify severe eye irritants, and OECD TGs on these two assays were adopted 
in 2009.  
Furthermore, from the four cytotoxicity- /cell function- based assays (NRR, FL, CM, RBC) evaluated 
in an ECVAM retrospective validation study, the CM was recommended by ESAC to be used in top-
down (discriminating severe eye irritants from all other classes) and bottom-up (discriminating non-
                                                 
1ECVAM (2005) Cosmetics technical report. ECVAM contribution. Available at: 
http://ec.europa.eu/enterprise/cosmetics/doc/antest_ecvam_2005v2.pdf (accessed on 29.11.2007). 
  
Eskes and Zuang (2005) Alternative (Non-animal) Methods for Cosmetics Testing: Current Status and Future Prospects. 
ATLA 33 Suppl. 1, pp.228. 
  
2 ECVAM technical report 2006-2007.Available at: http://ecvam.jrc.ec.europa.eu/ under “Publications”, “ECVAM and EU 
Policies”, accessed on 25.05.2009. 
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irritants from all other classes) approaches for defined applicability domains, and the FL was 
recommended to be used in a top-down approach. Finally, from the two other assays (LVET and 
Ocular Irritection®) which underwent external validation and submitted to ECVAM for evaluation, the 
ESAC recommended that existing LVET data pertaining to the applicability domain of detergents and 
cleaning products are recommended as scientifically useful within a weight of evidence approach, as 
also foreseen in the CLP regulation, but that LVET is not recommended for the prospective generation 
of new data.  ESAC also recommended LVET as reference standard against which to develop in vitro 
assays for detergents and cleaning products. 
The Ocular Irritection® test method, on the other hand, further to the evaluation of the submission, 
ECVAM requested to provide additional information in a revised submission.  
A prospective validation study on two Reconstructed human Tissue models (EpiOcular™ and 
SkinEthic™ HCE) which were submitted to ECVAM by COLIPA, was initiated in December 2008 
and is currently on-going.   
 
Finally, testing strategies which combine the validated assays are currently under development and 
evaluation, with the aim to completely replace the animal test for eye irritation. 
 
For acute oral toxicity, previous findings from Halle’s Registry of Cytotoxicity (Halle, 2003) and the 
completed NICEATM/ECVAM validation study 
(http://iccvam.niehs.nih.gov/methods/acutetox/inv_nru_brd.htm) showed that the prediction from in 
vitro cytotoxicity data of low systemic toxicity is much better than the prediction of high systemic 
toxicity. Since 87% of new chemicals (New Chemicals Database) are non-toxic substances 
(Bulgheroni et al. 2009), the chance to correctly classify a new non-toxic substance with this in vitro 
assay is very high. Indeed, the preliminary results of the validation study to identify non-toxic 
substances (rat oral LD50 > 2000 mg/kg b.w.) show a high negative predictive value for the 3T3/NRU 
cytotoxicity assay. The results of the prevalidation of the testing strategy carried out within the 
ACuteTox project will become available only in June 2010. 
 
The endpoints described above are those falling under the 2009 deadline with regard to the animal 
testing ban and marketing ban on cosmetics tested on animals. Those which fall under the 2013 
deadline of the marketing ban are repeated-dose toxicity (including skin sensitisation and 
carcinogenicity), toxicokinetics and reproductive toxicology. 
 
Under the new circumstances of the Cosmetics Directive, where only alternative methods can be used, 
toxicokinetics and metabolism in vitro and in silico test systems are of crucial importance to discard 
artifactual findings secondary to the in vitro environment. A collaborative effort between industry, 
academia, the European Commission and the three validation bodies (ECVAM, ICCVAM and 
JACVAM) was therefore set up to validate an in vitro metabolic competent test system as an important 
building block in integrated testing strategies for the complex endpoints. 
 
For the endpoint on carcinogenicity, three variants of the cell transformation assay in vitro were 
validated according to modules 1 to 4 of the ECVAM modular approach and will shortly be submitted 
for ESAC peer review.  In the field of skin sensitisation, three promising in vitro methods [the Direct 
Peptide Reactivity Assay (DPRA), the human Cell Line Activation Test (h-CLAT) and the Myeloid 
U939 Skin Sensitisation Test (MUSST)] were sufficiently optimised by industry and were accepted in 
2009 by ECVAM for entering prevalidation.  
In the area of reproductive toxicology, some promising methods, which were developed under 
Reprotect, an EU-funded collaborative research project in which ECVAM was also involved, will be 
submitted to ECVAM for (pre)validation and some in vitro methods for the identification of endocrine 
disruptors are currently under validation. A reduction in the number of animals used for reproductive 
toxicity testing is envisaged with the ongoing work that advocates a modular approach to the extended 
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one-generation reproduction study (Moore et al., 2009). For the complex endpoints, the lack of enough 
robust and relevant methods to fully replace the animal tests remains a challenge.  
 
Table 1 represents the current international state-of-play in the validation and acceptance of alternative 
methods for the human health effects of concern to the Cosmetics Directive.  
 
Table 2 represents the test (pre-)submissions received at ECVAM during 2008-beginning of  2010.  
 
 
Table 1. International Validation and Acceptance of Alternative Methods 1998-20103 
 
Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
Eye irritation 
 
     
Bovine Corneal 
Opacity and 
Permeability 
(BCOP) Test 
Method 
 
ICCVAM peer 
review and report 
(2007); ESAC 
statement (2007) 
US acceptance in 
2008 
 OECD TG 
437 (2009) 
EU Test 
Method B.47 
Isolated Chicken 
Eye (ICE) Test 
Method 
 
ICCVAM peer 
review and report 
(2007); ESAC 
statement (2007) 
US acceptance in 
2008 
 OECD TG 
438 
(2009) 
EU Test 
Method B.48 
EpiOcular assay  
 
ECVAM-COLIPA 
validation on 
going (2008-
2011) 
    
SkinEthic assay  
 
ECVAM-COLIPA 
validation on 
going (2008-
2011) 
    
Fluorescein 
Leakage assay 
 
ECVAM 
validation 
completed. 
ESAC statement 
2009 
  SPSF 
submitted 
to OECD 
(2010) 
Draft TG in 
preparation 
 
Cytosensor 
Microphysiometer 
assay 
 
ECVAM 
validation 
completed. 
ESAC statement 
2009 
Recommendation
s to Federal 
Agencies: in 
progress 
 SPSF 
submitted 
to OECD 
(2010) 
Draft TG in 
preparation 
 
Neutral Red 
Release assay 
ECVAM 
validation 
completed in 
2009 (negative 
outcome) 
 
    
Red Blood Cell 
test 
ECVAM 
validation 
completed in 
2009 (negative 
outcome) 
 
    
Low Volume Eye 
Test 
ECVAM 
validation 
Transmittal of 
ICCVAM 
   
                                                 
3 Updated April 2010 
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Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
completed in 
2007. 
ESAC statement 
2009. 
ICCVAM 
international peer 
review (2009) 
reccomendations 
to U.S. Federal 
agencies: in 
progress. 
Acceptance in 
US expected late 
2010 
Cytotoxicity test: 
Short Time 
Exposure (STE) 
test 
 
JaCVAM-
sponsored 
validation study 
planning.  
    
Cytotoxicity test: 
SIRC cells 
 
JaCVAM peer 
review ongoing 
    
Cytotoxicity test: 
three-dimensional 
dermal model 
(MATREX) 
 
JaCVAM peer 
review ongoing 
    
Use of 
anesthetics, 
analgesics, and 
humane endpoints 
in the Draize eye 
test; Recommen-
dations for routine 
use 
 
NICEATM-
ICCVAM.  
ICCVAM 
international peer   
review (2009) 
 
Transmittal of 
ICCVAM 
recommendation
s to U.S. Federal 
agencies: in 
progress. 
Acceptance in 
U.S. expected 
late 2010 
 SPSF 
submitted 
to OECD 
(2010) 
 
In vitro methods 
for identification of 
moderate and mild 
irritants and 
substances not 
labeled as irritants: 
Recommend-
dations for further 
optimization and 
studies 
BCOP 
ICE 
IRE 
HET-CAM 
 
NICEATM-
ICCVAM. 
ICCVAM 
international 
peer review 
(2009) 
 
Transmittal of 
ICCVAM 
recommendation
s to U.S. Federal 
agencies: in 
progress. 
Acceptance in 
U.S. expected 
late 2010 
   
In vitro approach 
for categorization 
of anti-microbial 
cleaning products: 
recommend-
dations for further 
studies 
 
NICEATM-
ICCVAM 
 
ICCVAM 
international 
peer review 
(2009) 
 
Transmittal of 
ICCVAM 
recommendation
s to U.S. Federal 
agencies: in 
progress. 
Acceptance in 
U.S.expected 
late 2010 
   
Skin Corrosion 
 
     
CORROSITEX 
Skin Corrosivity 
Test 
ICCVAM peer 
review and report 
(1999); ESAC 
statement (2000) 
US acceptance in 
2000 
 OECD TG 
435 (2006) 
 
EpiSkin Skin 
Corrosivity Test 
ECVAM 
validation; ESAC 
  OECD TG 
431 (2004) 
EU Test 
Method B.40 
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Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
 statement 
(1998); ICCVAM 
review and report 
(2002) 
Bis 
EpiDerm Skin 
Corrosivity Test 
 
ECVAM 
validation; ESAC 
statement 
(1998); ICCVAM 
review and report 
(2002) 
  OECD TG 
431 (2004) 
EU Test 
Method B.40 
Bis 
SkinEthic Skin 
Corrosivity Test 
 
ECVAM 
validation/ESAC 
statement (2006) 
  OECD TG 
431 (2004) 
EU Test 
Method B.40 
Bis 
Rat Skin TER 
Corrosivity Test 
 
ECVAM 
validation; ESAC 
statement 
(1998); ICCVAM 
review and report 
(2002) 
  OECD TG 
430 (2004) 
EU Test 
Method B.40 
EST-1000 
(CellSystems) 
 
ESAC statement 
(2009) 
  OECD TG 
431 (2004) 
EU Test 
Method B.40 
Bis 
Skin irritation 
 
     
EpiSkin Skin 
Irritation Test 
 
ECVAM 
validation; ESAC 
statement (2007) 
 
 Accepted 
by 
Japanese 
Regulatory 
Acceptance 
Board 
OECD TG 
439 
approved 
by OECD 
WNT, 
March 
2010; 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010 
EU Test 
Method B.46 
EpiDerm Skin 
Irritation Test 
 
ECVAM 
validation; ESAC 
statement (2008) 
  OECD TG 
439 
approved 
by OECD 
WNT, 
March 
2010; 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010 
EU Test 
Method B.46 
SkinEthic RHE  
 
ECVAM 
validation; ESAC 
statement (2008) 
  OECD TG 
439 
approved 
by OECD 
WNT, 
March 
2010; 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010 
EU Test 
Method B.46 
LabCyte EPI-
MODEL24 in vitro 
test method 
JaCVAM-  
 sponsored  
 validation study  
  OECD 
Peer 
review 
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Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
  completed 2009 
 
finalised 
(May 2010) 
Investigation of in 
vitro dermal 
irritation assays to 
evaluate false 
negative 
corrosives from in 
vitro corrosivity 
tests 
EpiDerm 
EPISKIN 
SkinEthic   
RHE 
 
NICEATM-
ICCVAM. 
Study in 
progress 
    
Skin absorption/ 
penetration 
 
     
In vitro diffusion 
method for 
measuring skin 
absorption 
 
   OECD TG 
428 (2004) 
EU Test 
Method B.45 
Skin 
sensitisation 
 
     
Local Lymph Node 
Assay for skin 
sensitisation 
ICCVAM peer 
review and report 
(1999);  ESAC 
statement (1999) 
US acceptance in 
1999 
 OECD TG 
429 (2002) 
EU Test 
Method B.42 
Reduced Local 
Lymph Node 
Assay for skin 
sensitisation 
ESAC statement 
(2007); ICCVAM 
peer review and 
report (2008) 
US acceptance in 
2010 
 Under 
discussion 
within the 
revision of 
TG 429 
 
MUSST ECVAM 
validation started 
in 2009 
    
h-CLAT ECVAM 
validation started 
in 2009 
    
Direct Peptide 
Reactivity Assay 
ECVAM 
validation started 
in 2009 
    
Updated Murine 
local lymph node 
assay (LLNA) for 
skin sensitization 
(20% reduction) 
 
NICEATM-
ICCVAM. 
ICCVAM 
International peer 
review (2008) 
U.S. acceptance 
(2010) 
 
 OECD TG 
429 
(updated) 
approved 
by OECD 
WNT, 
March 
2010; 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010 
 
Nonradioactive 
LLNA protocol 
(LLNA: BrdU-Flow 
Cytometry) 
NICEATM-
ICCVAM. 
ICCVAM 
international 
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Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
 peer review, 
2009 
Data audit and 
interlaboratory 
study planned 
Nonradioactive 
LLNA protocol 
(LLNA: BrdU-
ELISA) 
 
JaCVAM 
(validation 
study); 
NICEATM-
ICCVAM 
(international 
peer review 
2009) 
Transmittal of 
ICCVAM 
recommendation
s to U.S. Federal 
agencies: in 
progress 
 
Acceptance 
by 
Japanese 
Regulatory 
Acceptance 
Board 
pending 
OECD TG 
442B 
approved 
by OECD 
WNT 
March 
2010. 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010 
 
Nonradioactive 
LLNA protocol, 
LLNA:DA 
 
JaCVAM 
(validation 
study); 
NICEATM-
ICCVAM 
(international 
peer review 
2009) 
Transmittal of 
ICCVAM 
recommendation
s to U.S. Federal 
agencies: in 
progress 
Accepted 
by 
Japanese 
Regulatory 
Acceptanc
e Board  
(2008)  
 
OECD TG 
442A 
approved 
by OECD 
WNT 
March 
2010. 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010 
 
Harmonized 
performance 
standards for  
LLNA 
 
NICEATM-
ICCVAM; 
ECVAM; 
JaCVAM 
 
Endorsed by 
ESAC and 
ICCVAM 
U.S. acceptance 
in 2010  
Draft 
OECD 
update to 
TG 429 
approved 
by OECD 
WNT 
March 
2010; 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010 
 
Acute 
phototoxicity 
 
     
3T3 NRU 
Phototoxicity Test 
(photo-irritation) 
ESAC Statement 
(1998) 
  OECD TG 
432 (2004) 
EU Test 
Method B.41 
3T3 NRU 
Phototoxicity Test:  
Application to UV 
Filter Chemicals 
ESAC Statement 
(1998) 
  OECD TG 
432 (2004) 
EU Test 
Method B.41 
Tiered testing 
strategy to predict 
phototoxicity (3T3 
NRU PT and 
reconstructed 
human epidermis 
models) 
 
ECVAM 
feasibility study 
completed 
    
Produced reactive 
oxygen species 
JaCVAM-
sponsored 
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Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
(ROS) and 
photostability 
study 
validation study 
planning 
Test method 
battery to predict 
phototoxicity 
(yeast growth 
inhibition 
phototoxicity 
assay and red 
blood cell 
photohemolysis 
assay) 
 
JaCVAM 
Japanese 
Regulatory 
Acceptance 
Board 
recommended 
additional work 
be performed 
    
Acute Toxicity 
 
     
Up and Down 
Procedure (UDP) 
ICCVAM peer 
review and report 
(2001); ESAC 
statement (2007) 
Yes, 
agency 
acceptance  
 OECD TG 
425 (2001) 
 
Fixed Dose 
Procedure (FDP) 
ICCVAM  (2001); 
ESAC statement 
(2007) 
  OECD TG 
420 (2001) 
EU Test 
Method B.1 
Bis 
Acute Toxic Class 
Method (ATC) 
ICCVAM (2001); 
ESAC statement 
(2007) 
  OECD TG 
423 (2001) 
EU Test 
Method B.1 
Tris 
In vitro cytotoxicity 
test (3T3 Neutral 
Red Uptake ) to 
estimate starting 
doses for oral 
acute systemic 
toxicity 
NICEATM-
ECVAM 
Validation Study; 
ICCVAM peer 
review and report 
(2008) 
Yes, agency 
endorsement  
 Guidance 
document 
adopted in 
2010 
 
In vitro cytotoxicity 
test (NHK Neutral 
Red Uptake ) to 
estimate starting 
doses for oral 
acute systemic 
toxicity 
NICEATM-
ECVAM 
Validation Study; 
ICCVAM peer 
review and report 
(2008) 
Yes, agency 
endorsement 
 Guidance 
document 
adopted in 
2010 
 
In vitro cytotoxicity 
test (3T3 Neutral 
Red Uptake) for 
identifying 
substances with 
acute oral LD50 > 
2000 mg/kg b.w 
ECVAM follow-
up validation 
study completed 
(2009) 
(BRD in 
preparation) 
    
Granulocyte 
macrophage- 
Colony Forming 
Unit for Predicting 
Acute Neutropenia 
in Humans 
ECVAM 
validation  
ESAC statement 
(2006) 
    
Up-and-Down 
Procedure (acute 
dermal toxicity) 
 
NICEATM-
ICCVAM. 
Collecting acute 
dermal toxicity 
data for use in 
computer 
simulations for 
future validation 
    
Acute inhalation 
toxicity 
OECD TG 403 
(Revised version 
  OECD TG 
403 (2009) 
 
 10
Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
 adopted, 2009) 
Inhalation toxicity - 
acute toxic class 
method 
 
Adopted as 
OECD Test 
Guideline (TG) 
436 (2009) 
  OECD TG 
436 (2009) 
 
Genotoxicity/ 
mutagenicity 
 
     
In vitro 
micronucleus test 
 
ECVAM 
validation; ESAC 
statement (2006) 
  OECD TG 
487 
approved 
by OECD 
WNT by 
written 
procedure 
(2009) 
Adoption 
by OECD 
JM 
foreseen 
Sept. 2010  
Mentioned in 
Annex VIII of 
Reg. 
1907/2006 
 
Comet assays in 
vitro and in vivo 
(2 test methods) 
JaCVAM 
validation study 
in progress on in 
vivo and in vitro 
methods; 
coordination with 
ICCVAM and 
ECVAM 
    
Genotoxicity 
assays  (COMET 
in vitro and 
micronucleus test 
in vitro) in 3D skin 
models (2 tests) 
COLIPA/ECVAM 
Validation study 
ongoing 
    
Improvement of 
the in vitro test 
battery for 
genotoxicity 
ECVAM 
Analysis of 
cytotoxicity top 
dose in in vitro 
genotoxicity tests 
on going 
    
Carcinogenicity 
 
     
Cell 
Transformation 
Assay pH 6.7 
 
ECVAM 
prevalidation 
completed. 
ESAC peer 
review to initiate 
in 2010 
    
Cell 
Transformation 
Assay pH 7 
 
ECVAM 
prevalidation 
completed. 
ESAC peer 
review to initiate 
in 2010 
    
Cell 
Transformation 
Assay Balb/c 3T3 
cell  
 
ECVAM 
prevalidation 
completed. 
ESAC peer 
review to initiate 
in 2010 
    
BHAS cell 
transformation 
JaCVAM 
validation study 
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Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
assay 
 
in progress with 
ECVAM 
participation 
Toxicokinetics/ 
metabolism 
 
     
In vitro hepatic 
biotransformation 
enzyme induction 
[Hepa RG (in-
house); Hepa RG 
(commercial) and 
cryopreserved 
human 
hepatocytes] (3 
test methods) 
Validation study 
on-going 
(ECVAM led with 
ICCVAM and 
JaCVAM 
involvement) 
    
Reproductive 
toxicology 
 
     
In Vitro 
Embryotoxicity 
Tests employing 
micromass culture, 
rat embryo 
cultures, and 
embryonic stem 
cells 
ECVAM 
validation 
completed. 
ESAC statement 
in 2001 
    
LUMI CELL® 
estrogen receptor 
transcriptional 
activation assay: 
agonist and 
antagonist 
protocols 
International 
validation study 
in progress 
(NICEATM, 
JaCVAM, 
ECVAM) 
 
    
MELN ® estrogen 
receptor 
transcriptional 
activation assay: 
agonist and 
antagonist 
protocols 
Validation study 
will start in 2010 
(ECVAM) 
    
Extended-F1 
generation test 
Validation under 
the OECD 
umbrella (with 
ECVAM 
participation) 
completed (2009) 
    
CertiChem MCF-7 
cell proliferation 
assay for the 
detection of 
human estrogen 
receptor agonists 
and antagonists 
 
NICEATM-
ICCVAM. 
International 
validation study 
in progress. 
Independent 
peer review 
planned March 
2011 
    
Stably transfected 
human estrogen 
receptor-
αtranscriptional 
activation assay 
for detection of 
estrogenic 
Validation under 
the OECD 
umbrella 
(JaCVAM 
coordinated) 
completed 
  OECD TG 
455 (2009) 
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Test Method per 
human health 
effect 
 
Current status Regulatory acceptance 
  US 
 
Japan OECD  EU 
agonist-activity of 
chemicals 
Stably transfected 
human estrogen 
receptor-
αtranscriptional 
activation assay 
for detection of 
anti-estrogenic 
activity of 
chemicals 
International 
validation study 
in progress 
(JaCVAM 
coordinated) 
 
    
 
 
 
Table 2. Test (pre-)submissions received at ECVAM from 2008 to first quarter of 2010 
 
 
Test Method per human health effect 
 
Year of 
submission to 
ECVAM 
 
Status of test method 
 
Rat recombinant androgen receptor binding assay 
for the detection of compounds with 
(anti)androgenic potential 
 
 
2010 
 
Full submission awaited 
Transactivation assay for the detection of 
compounds with (anti) androgenic potential using 
PALM cells 
 
 
2010 
 
Full submission awaited 
Test system for the evaluation of organophospates 
(OPs)- induced neurotoxicity following inhibition of 
critical esterases, acetylcholinesterase (AChE) and 
neuropathy target esterase (NTE) measured by in 
vitro approach 
 
 
2009 
 
Full submission awaited 
ERalpha CALUX® assay for the prediction of the in 
vivo estrogenic activity of chemicals 
 
 
2009 
 
Full submission awaited 
VitroDerm RhE model for skin irritation testing  
2009 
 
Incomplete pre-submission 
 
EST-1000 RhE model for skin irritation testing 
 
 
2009 
 
Full submission awaited 
GreenScreen for genotoxicity testing 2009 Full submission awaited 
Biobide- Automated screening to detect 
cardiotoxicity in Zebrafish 
 
2009 Full submission awaited 
Direct Peptide Reactivity Assay for skin 
sensitisation testing 
 
2009 Under validation 
Myeloid U939 Skin Sensitisation Test (MUSST) 2009 Under validation 
Chemical reactivity measurement using the 
Glutathione (GSH and GSSG) peptide reactivity 
HPLC-MS assay 
 
 
2009 
 
Test did not progress to 
validation 
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Test Method per human health effect 
 
Year of 
submission to 
ECVAM 
 
Status of test method 
 
Chemical reactivity measurement using the 
cysteine or lysine peptide binding HPLC assay 
 
 
2009 
Under validation 
MELN® transactivation assay for the detection of 
compounds with (anti) estrogenic potential 
 
 
2009 
 
Full submission awaited 
Ocular Irritection® assay for eye irritation testing 
 
2009 Under external validation 
In vitro hepatic biotransformation enzyme induction 
- HepaRG  
(commercial) for toxicokinetics/metabolism testing 
 
 
2008 
 
Under validation 
In vitro hepatic biotransformation enzyme induction 
- HepaRG  
(in-house) for toxicokinetics/metabolism testing 
 
 
 
2008 
 
Under validation 
In vitro hepatic biotransformation enzyme induction 
- cryopreserved human  
hepatocytes for toxicokinetics/metabolism testing 
 
 
2008 
 
Under validation 
In vitro diffusion method for measuring skin 
absorption 
 
2008 Full submission awaited 
Valitox test for acute toxicity 
 
2008 Full submission awaited 
CPA-I test for respiratory sensitisation testing 
 
2008 Test did not meet ECVAM’s 
priorities 
EpiOcular™ model for eye irritation testing 
 
2008 Under validation 
SkinEthic™Human Corneal Epithelium (HCE) for 
eye irritation testing 
 
2008 Under validation 
Assay for the assessment of DNA modifying agents 
for genotoxicity testing 
 
 
2008 
Test did not meet ECVAM’s 
priorities 
Test for the identification of endocrine disrupting 
chemicals for reproductive toxicity testing 
 
 
2008 
Further clarifications on test 
pre-submission awaited 
The Chorioallantoic Membrane Vascular Assay 
(CAMVA) for eye irritation testing 
 
 
2008 
 
Full submission awaited 
human Cell Line Activation Test (h-CLAT) for skin 
sensitisation testing 
2008 Under validation 
VITOSENS- Skin sensitisation testing 
 
2008 Under external validation 
The Porcine Corneal Opacity Reversibility Assay 
(PorCORA) for eye irritation testing 
 
 
2008 
 
Submission awaited 
SkinEthic RHE for skin irritation testing 
 
2008 Validated and regulatory 
accepted 
 
Modified EpiDerm for skin irritation testing 
 
2008 
 
Validated and regulatory 
accepted 
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INTRODUCTION 
 
The animal testing ban of cosmetic ingredients came into force on 11 March 2009, for all human 
health effects. The marketing ban of cosmetic ingredients tested on animals became effective at the 
same date for all human health effects with the exception of repeated-dose toxicity (including skin 
sensitisation and carcinogenicity), reproductive toxicity and toxicokinetics. For these specific health 
effects, a deadline of 10 years after entry into force of the Directive is foreseen, i.e., 11 March 2013, 
irrespective of the availability of alternative non-animal tests, but which could be postponed through 
Codecision procedure in case of technical problems in meeting this deadline. Noteworthy, in Europe, 
according to Directive 2003/35/EC, cosmetic finished products cannot be tested on animals anymore 
since 2003 (EU, 2003). 
 
Article 9 of Directive 2003/15/EC amending Council Directive 76/768/EEC on the approximation of 
the laws of the Member States relating to cosmetic products for the seventh time stipulates that “every 
year the Commission shall present a report to the European Parliament and the Council on progress 
made in the development, validation and legal acceptance of alternative methods……”. The ECVAM 
technical report is prepared to support the Commission Annual report by providing information on the 
current status of alternative methods.    
 
During 2008-2009, ECVAM progressed its activities related to validation, development and 
optimisation of alternative methods. Furthermore, during the last two years ECVAM became also very 
proactive in the regulatory acceptance of alternative methods.  
 
The present report is divided into two parts. The first part covers the human health effects which fall 
within the 2009 deadline according to the marketing ban imposed by the Cosmetics Directive and the 
subsequent reports on establishing a timetable for phasing out animal testing (EC, 2004a). The second 
part describes those which fall within the 2013 deadline. It should be kept in mind that according to the 
7th Amendment of the Cosmetics Directive, the animal testing ban will be effective in 2009 for all the 
human health endpoints, irrespective of the availability of alternative methods.  
 
 
1.  HUMAN HEALTH EFFECTS FALLING UNDER THE 2009 
 DEADLINE 
 
1.1 ACUTE TOXICITY 
 
In the area of acute toxicity, one of the activities during 2008-2009 was the continuation of the EU 
Integrated Project ACuteTox.  
 
The work carried out in this project consisted in the generation of in vitro data using different cell 
systems and in silico models (http://www.acutetox.org/). By the end of 2008, 57 chemicals were tested 
with a number of functional tests covering absorption, distribution, excretion, metabolism and specific 
organ toxicity, such as haemato-, neuro-, nephro- and hepatotoxicity. The data generated were stored 
in a novel database developed (Acutoxbase) within the project. This database contains a full set of data 
regarding the 97 ACuteTox reference chemicals, including molecular structure, physicochemical 
properties and summary descriptions on use, toxicity and in vivo biokinetics. Moreover, the database 
contains data sets from acute oral toxicity studies in vivo, from human blood poisoning reports, from in 
vitro experiments and different SOPs for in vitro assays (Kinsner-Ovaskainen et al., 2009).  
 
During the five years of the project, a very large number of in vitro assays were used to test a set of 57 
chemicals. The generated data were used to assess the within-laboratory variability, the preliminary 
predictive capacity, and in some cases also the between-laboratory variability of each in vitro assay. 
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The outcome of this phase of the project is a large toolbox of in vitro methods, some of them evaluated 
to the level of prevalidation.  
 
Moreover, based on a statistical analysis of this large dataset, a list of in vitro and in silico methods 
was selected in the course of 2009, and three proposals for in vitro tiered testing strategies were 
defined. The choice of assays was done according to their reproducibility and reliability, and most 
importantly, according to their potential to classify chemicals into the different acute oral toxicity 
categories (EU and GHS). 
 
- Neutral Red Uptake in 3T3 mouse fibroblasts (general cytotoxicity). 
- Cytokine release (IL-1, TNF-α, IL-6) in human whole blood (immunotoxicity). 
- Cytomic panel for Cytotoxicity Screening (Ca2+ uptake, mitochondrial and plasma membrane 
potential) in A.704 (human kidney adenocarcinoma), HepG2 (human hepatoma), SH-SY5Y 
(human neuroblastoma) cells. 
- Cytomic panel Oxidative stress (intracellular peroxidative activity, intracellular levels of 
superoxide anion, oxidized DNA base 8-oxoguanine) in HepG2, SH-SY5Y  and A.704 cells. 
- Inhibition of colony forming unit efficiency in human cord blood-derived cells stimulated with 
granulocyte/monocyte-colony stimulating factor (CBC/CFU-GM). 
- A multiparametric high content analysis in rat brain aggregates, comprising (i) mRNA 
expression for the genes heat-schock protein 32 (HSP32), glial fibrillary acidic protein (GFAP), 
neurofilaments (NF-H), and myelin basic protein (MBP); (ii) the rate of global RNA synthesis 
(i.e., uridine incorporation into total RNA) (neurotoxicity). 
- MTT assay in rat hepatocytes (metabolism).  
- Kinetic parameters: volume of distribution, protein binding, clearance (in vitro metabolic 
stability assay), and oral absorption (using in vitro Caco-2 cells and neuronal networks – 
human intestinal absorption [HIA]) for the estimation of the oral dose from the effective 
concentration observed in vitro. 
- The estimation of compound passage through the blood-brain barrier using neuronal networks 
(LogBB) (for neurotoxicity assays). 
 
Further work will focus mainly on the assessment of the predictive capacity of the proposed tiered 
testing strategies and the identification of the combination that gives the best prediction. During this 
phase, the methods identified as promising building blocks for the testing strategy, will be challenged 
with a new set of coded 32 compounds.  
 
The proposed combinations will be challenged retrospectively with the new data generated during this 
exercise, in order to identify the best performing combination (2010). 
 
As a follow-up study to the international validation study on the prediction of acute toxicity by 
cytotoxicity assays and taking into consideration the high prevalence of non-toxic substances in the 
New Chemicals Database (87% with LD50 > 2000 mg/kg), ECVAM has commissioned in 2008, a 
validation study in which 57 industrial chemicals (of which 43% are cosmetic ingredients) were tested 
to assess the predictive capacity of the validated 3T3/ NRU cytotoxicity assay to discriminate between 
toxic/hazardous (LD50 < 2000 mg/kg) and non-toxic (LD50 > 2000 mg/kg) substances. The validated 
protocol of the test was performed manually at Health & Safety Laboratory (UK) and was also 
established on the robotic testing facility at the Institute for Health and Consumer Protection, and this 
automated version was evaluated using the same set of chemicals. A third laboratory in the US 
assessed an abbreviated version of the validated 3T3/NRU protocol, which is less costly and more 
industry-friendly. The testing was finalised in June 2009 and data analysis is ongoing. The preliminary 
results show relatively high negative predictive values (90%). However, it is important to note that the 
rate of false positives is also high (65%). 
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Following the initiatives undertaken by the pharmaceutical industry to waive the acute oral toxicity 
testing before going to clinical studies by using information from other in vivo studies, ECVAM 
performed in 2008 an investigation to identify non-toxic compounds (LD50 > 2000 mg/kg) using 
information from 28-days repeated dose toxicity studies. A Non Observed Adverse Effect Level 
threshold was set that allowed the correct identification of 63% of non-toxic compounds, while only 
less than 1% of harmful compounds were misclassified as non-toxic. The proposed approach could 
have an immediate impact for the testing of cosmetic ingredients as it could filter more than 50% of 
substances (Bulgheroni et al. 2009). 
 
In addition, during 2009, ECVAM has performed a retrospective data analysis of multi-route acute 
studies in order to evaluate the concordance among regulatory classifications for acute, dermal and/or 
inhalation toxicity. 1569 chemicals retrieved from the New Chemicals Database were included in this 
anlaysis. The results showed that the concordance among oral and dermal route for non classified 
substances is 100% and only for one substance the dermal classification was more severe than for the 
oral route (manuscript in preparation). Similar findings have been recently published by Creton et al. 
(2010) with a small chemical data set, confirming that acute dermal studies do not add value beyond 
oral data for hazard classification of chemicals. 
 
1.2 SKIN IRRITATION/CORROSION 
 
The ECVAM skin irritation validation study (SIVS) ended successfully in May 2006 (Spielmann et al., 
2007; Eskes et al., 2007). Further to peer-review of the study by the ECVAM Scientific Advisory 
Committee (ESAC), in April 2007, ESAC issued a statement on the scientific validity of the EpiSkin™ 
assay as being a reliable and relevant stand-alone test for predicting rabbit skin irritation, when the 
endpoint is evaluated by MTT reduction, and for being used as a replacement for the Draize Skin 
Irritation Test (OECD TG 404 & Method B.4 of Annex V to Directive 67/548/EEC) for the purposes 
of distinguishing between R38 skin irritant and no-label (non-skin irritant) test substances (ESAC, 
2007a).  
 
The EpiDerm™ test method was considered to reliably identify skin irritants due to its high specificity, 
but negative results might require further testing [e.g. according to the tiered strategy, as described in 
the OECD TG 404, (OECD, 2004a)]. The ESAC recommended that improvement of the EpiDerm™ 
protocol should be made to increase the level of sensitivity. Thus, the protocol of the EpiDerm™ assay 
was optimised by the test developers and the assay underwent an external validation study in view of 
upgrading the test to a full replacement test. The study was submitted to ECVAM in April 2008 in 
view of ESAC peer review. In November 2008, upon completion of the peer review process, ESAC 
issued a statement on the scientific validity of the modified EpiDerm™ test method as a full 
replacement test (ESAC, 2008a). 
 
Finally, the similar SkinEthic™ RHE test method for skin irritation testing underwent an external 
catch-up validation study, was independent peer-reviewed and an ESAC statement on its scientific 
validity as a full replacement test was issued in November 2008 (ESAC, 2008a). 
 
An EU Test Method on Reconstructed human Epidermis (RhE) test methods for skin irritation testing 
was drafted and submitted to the EU National Coordinators of Testing Methods in December 2007. 
Test Method B.46 In Vitro Skin Irritation: Reconstructed Human Epidermis Model Test, including the 
three validated RhE test methods (EpiSkin™, EpiDerm™ and SkinEthic™ RHE) was officially 
introduced into the EU Test Method Regulation (COM regulation 440/2008/EC) in July 2009 (EC, 
2009). The consequent adoption of three validated in vitro test methods as stand-alone tests for 
replacing the skin irritation animal test will be of utmost importance to meet the challenges of the 7th 
Amendment to the Cosmetics Directive. The Commission also submitted a test guideline to the OECD 
which has been included in the OECD Test Guidelines Programme. Work in this forum is progressing 
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well: two OECD expert meetings for discussing the draft OECD TG were already held and the draft 
TG will be submitted to the WNT for adoption in March 2010. 
 
Recently, ESAC issued a statement (ESAC, 2009a) on the scientific validity of the EpiSkin™, the 
EpiDerm™ and the SkinEthic™ RHE test methods as being reliable and relevant stand-alone tests for 
predicting rabbit skin irritation under the EU CLP regulation adopting the GHS classification system 
(EC, 2008). In the EU, the UN GHS system as applicable to all authorities is directly transposed and 
implemented through the Regulation on the Classification, Labelling and Packaging of Substances and 
Mixtures (CLP 498 Regulation EC 1272/2008) which was adopted in December 2008, came into force 
on 20 January 2009 and will, after a transitional period, replace the previous EU legislations for the 
classification of 500 substances and mixtures (i.e. preparations). In agreement with the UN GHS 
system, the CLP system continues to use one irritant category. However, according to the new rules for 
skin irritation classification and labelling (C&L), the cut-off 
503 score to distinguish between no-category and category 2 substances was shifted to 2.3 (UN GHS 
or CLP) from a value of 2.0 (previous EU system). Consequently substances with an in vivo score 
between 2.0 and 2.3 that were considered irritant under the previous EU system are now considered 
non-irritants under UN GHS, which does not use the optional Category 3 (Griesinger et al., 2010). 
 
A presubmission of another RhE test method for skin irritation testing [Epidermal Skin Test (EST)-
1000] was received at ECVAM in September 2009 and a further submission of an RhE test method 
(StratiCELL EPI/001) is expected soon.  
 
This raises the question on the level of priority that should be given to the validation of additional test 
methods which are similar to the already validated and accepted ones. 
 
In the field of skin corrosion, an additional similar test method  (EST-1000) to the validated ones 
(EpiSkin™, EpiDerm™ and SkinEthic™ RHE skin corrosion tests) was endorsed as being able to 
distinguish between corrosive and non-corrosive chemicals within the context of OECD Test guideline 
431 in 2009 (ESAC, 2009b). 
 
To advance the development of new biomarkers which could be used in reconstructed human 
epidermis test methods, ECVAM assessed two promising new predictive technologies in the 
framework of its in-house research: toxicogenomics as well as toxico-metabonomics. The outcome of 
the toxicogenomics approach was published in 2007 (Borlon et al., 2007).  
 
 
 
1.3 EYE IRRITATION 
 
Substantial progress has also been made in the field of eye irritation as described below. ECVAM is 
working in close collaboration with ICCVAM, COLIPA and the industry in general, in order to 
streamline and harmonise global validation efforts and avoid duplication of work. 
 
1.3.1 Testing Strategies 
 
Promising testing strategies for eye irritation were identified during an ECVAM Expert Meeting 
involving more than 30 participants from industries, CROs, regulators, academia and animal welfare 
organisations in 2005 (Scott et al., 2010). The expert meeting was convened to allow developers/users 
to nominate methods to be considered as a basis for an overall testing strategy. Assays were evaluated 
and categorised on the basis of their applicability domains (e.g., categories of severity of irritation, 
modes of action, chemical class, physicochemical compatibility). The analyses were based on the data 
developed from current practice and published studies, expert opinion, the ability to predict depth of 
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injury (within the applicable range of severity), modes of action that could be addressed and 
compatibility with different physico-chemical forms. The difficulty in predicting the middle category 
of irritancy (e.g. R36, GHS Categories 2A and 2B) was recognized. The testing scheme proposes using 
a Bottom-Up (begin with using test methods that can accurately identify non-irritants) or Top-Down 
(begin with using test methods that can accurately identify severe irritants) progression of in vitro tests, 
based on expected irritancy of substances as primarily identified by their physico-chemical properties. 
Irrespective of the starting point, the approach would identify non-irritants and severe irritants, leaving 
all others to the (mild/moderate) irritant GHS 2/R36 categories.  
 
Fifteen assays were nominated which can be divided in four major groups: cytotoxicity- and cell 
function- based assays, reconstructed human tissue models, organotypic assays and other assays.  
 
The performances and applicability domains of individual alternative methods which are considered 
sufficiently promising to populate the proposed testing strategies were, or are currently being, 
determined through validation studies (Zuang et al., in press). 
 
1.3.2 Evaluation of in vitro assays 
 
Two organotypic assays, the Bovine Corneal Opacity and Permeability (BCOP) assay, and the Isolated 
Chicken Eye (ICE) test were endorsed by ESAC in April 2007 for the identification of ocular 
corrosives and severe irritants (ESAC, 2007b). Such statement was based on the results and 
conclusions from the ICCVAM retrospective validation study carried out in collaboration with 
ECVAM from 2003-2006. OECD Test Guidelines on the two test methods were adopted in 2009. For 
the two other organotypic assays evaluated, the Hen’s Egg Test on the Chorio-allantoic Membrane 
(HET-CAM) assay and the Isolated Rabbit Eye (IRE) test, ESAC requested that further work was 
performed before a statement on their scientific validity to identify ocular corrosives and severe 
irritants could be made. With regard to the evaluation of the four organotypic assays for identifying 
mild or non irritants, a retrospective analysis of the collected data was carried out by ICCVAM. In 
May 2009, the ICCVAM Ocular Peer Review Panel recommended BCOP for the identification of non-
classified materials. None of the test methods was recommended for full replacement, because none of 
the methods is able to identify the mild/moderate ranges of ocular irritancy. 
At ECVAM, follow-up work on further improvements of the prediction models and analyses for 
prediction of all ranges of irritancy, using data mining techniques, is currently ongoing. 
 
The retrospective validation of four cytototoxicy- and cell function- based assays, i.e., the Neutral Red 
Release (NRR), the Red Blood Cell (RBC), the Fluorescein Leakage (FL) and the Cytosensor 
Microphysiometer (CM) test methods took place between May 2006 and October 2008. The study was 
based on the retrospective collection of existing data compiled according to the ECVAM modular 
approach to validation and weight-of-evidence principles (Hartung et al., 2004; Balls et al., 2006).  
Based on the final results, recommendations were made by the Validation Management Group on the 
validity of the NRR (INVITTOX Protocol 54 and PREDISAFE™) and FL (INVITTOX Protocol 120) 
to initiate a bottom-up approach, discriminating chemicals not classified as irritants (GHS and EU non-
classified) from all irritant classes, and the CM (INVITTOX Protocol 102 modified) and FL 
(INVITTOX Protocol 71) to initiate a top-down approach, discriminating severe irritants (GHS Cat 1, 
EU R41) from all other classes, for defined applicability domains. 
 
In July 2009, ESAC endorsed the CM (INVITTOX Protocol 102 modified) and the FL (INVITTOX 
Protocol 71) as scientifically valid for use as an initial step within a top-down approach to identify 
ocular corrosives and severe irritants (GHS Cat 1, EU R41, EPA Cat I) from all other classes, for 
water-soluble chemicals (substances and mixtures). Furthermore, the CM (INVITTOX Protocol 102 
modified) was considered to have been scientifically validated for use as an initial step within a 
bottom-up approach to identify chemicals not classified as irritants (GHS no category, EU no category, 
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EPA Cat IV) from all irritant classes, only for water-soluble surfactants, and water-soluble surfactant-
containing mixtures (ESAC, 2009c). 
 
On the basis of a thorough evaluation of the data compiled in the course of the ECVAM validation 
study, the ESAC concluded that the CM test method does not correctly identify moderate and mild 
ocular irritants (EU: R36; GHS: Cat 2A/B; EPA: Cat II/III). Therefore, the test method can only be 
employed to make decisions on two of the categories of the eye irritation classification schemes. 
Consequently, ESAC did not recommend this test method as a full replacement method. It should be 
noted in this context that the top-down and bottom-up approaches foresee the theoretical possibility of 
a default mild/moderate categorization (e.g. EU R36 or GHS Cat 2) of all those chemicals neither 
identified as ocular corrosives and severe irritants nor as "not classified" in the first two tiers of the 
strategy. However, since the false negative rate of the CM was high (9-55%) when initiating a top-
down approach and the false positive rate was high (50-69%) when initiating a bottom-up approach, 
the possibility to use the method for default categorization was excluded. The test method can thus not 
be considered a full replacement method on its own using the top-down and bottom-up approaches. 
 
For the FL (INVITTOX Protocol 71), additional testing and further refinement, in particular with 
respect to variability and definition of the applicability domain, by expanding the dataset of tested 
chemicals and direct comparison with in vivo data was recommended. With regard to the NRR 
(INVITTOX Protocol 54 and PREDISAFE™), RBC (INVITTOX Protocols 37 and 99) and FL 
(INVITTOX Protocols 82, 86 and 120), ESAC considered that the available evidence was insufficient 
to support a recommendation that they are ready for consideration for regulatory use. 
 
Similarly, the available evidence for Fluorescein Leakage INVITTOX Protocol 71 did not support a 
recommendation for its use to initiate a bottom-up approach for regulatory use. 
 
Two Reconstructed human Tissue (RhT) models, the SkinEthic™ Human Corneal Epithelium (HCE) 
and the EpiOcular™ OCL-200 model were positively reviewed by the ECVAM Eye Irritation Task 
Force who recommended protocol improvements prior to enter a formal validation study. The two 
assays have then undergone protocol optimisation and assessment in a multi-laboratory trial 
coordinated by COLIPA. Subsequently, the results were submitted to ECVAM in 2008 and were 
assessed in view of planning a prospective validation study. In December 2008, the ECVAM-COLIPA 
validation study on the two RhT models was initiated. The validation study foresees the testing of 104 
coded chemicals in three runs and in three laboratories. Six Validation Management Group meetings 
took already place since December 2008, where strategic decisions were taken including the definition 
of a study design and the type and number of chemicals to be tested, in view of starting the 
experimental phase of the study at the earliest possible date (Freeman et al., in press). 
 
The Ocular Irritection® assay, an in vitro method that mimics the biochemical phenomena of corneal 
proteins denaturation and disruption caused by irritant substances acting on the cornea, was submitted 
to ECVAM in January 2009. Further to the evaluation of the submission, ECVAM requested in May 
2009 to provide additional information in a revised submission. In order to fill the remaining data gaps 
identified in the submission, an external validation study on the Ocular Irritection® assay will be 
initiated beginning of 2010, with a view to submit the study to ECVAM for peer review by ESAC. 
 
1.3.3 Evaluation of a refinement method 
 
The Low Volume Eye Test (LVET) was first submitted to ECVAM in 2003. Further to ECVAM’s 
request for additional information and the recommendations from the ECVAM Task Force on Eye 
Irritation, a final dossier based on retrospective evidence compiled according to the Modular Approach 
was submitted to ECVAM by the test submitter in February 2007. The dossier was peer-reviewed by 
ESAC, who finally came to a consensus in July 2009. ESAC recommended the use of existing LVET 
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data for the use domain of household detergent and cleaning products and their main ingredients (e.g. 
surfactants) for making eye irritation classification and labelling decisions in a weight of evidence 
approach, and as reference data for the validation of in vitro test methods. However, ESAC 
recommended not generating new LVET data (ESAC, 2009d). 
 
1.3.4 Mechanistically-based assays 
 
Beside the development of testing strategies, ECVAM is also closely following the development of 
mechanistically relevant assays which cover other aspects of ocular toxicity that occur in vivo in order 
to address the currently existing mechanistic gaps (e.g. reversibility of effects due to tissue remodelling 
and modelling of the inflammatory responses or identification of mild irritant effects).  
 
1.4 GENOTOXICITY AND MUTAGENICITY 
 
The successful validation of the in vitro micronucleus test led to EU regulatory acceptance and to the 
rapid integration of the test into the REACH legislation. An OECD ad hoc expert meeting for the 
finalisation of the draft test guideline (TG 487) was held in Atlanta in October 2007. In 2008, the 
OECD WNT provisionally approved the draft Test Guideline, pending the outcome of the cytotoxicity 
measure [Relative Population Doubling (RPD) or Relative Increase in Cell Counts (RICC)] 
performance assessment, since the US had objected that the proposed methods for cytotoxicity 
measurements in draft TG 487, had not been adequately substantiated. To resolve this issue, a 
European Working Group coordinated by the UK agreed to develop data demonstrating the 
performance of these cytotoxicity measurement approaches. The US agreed to accept these methods if, 
after reviewing the data, it concurs that the developed data do substantiate their use. The experimental 
work was finalised and the results were presented at the International Workshop on Genotoxicity 
Testing (IWGT) which was held in Basel in August 2009. Test Guideline 487 has been approved by 
written procedure by the OECD Working Group of National Coordinators on 28 November 2009 and 
will therefore soon be adopted, which will lead to its widespread international application. According 
to the standard procedure, the micronucleus test in vitro will be introduced into the EU Test Method 
Regulation. 
Since the regulatory accepted in vitro assays produce a high rate of false positives, which need to be 
confirmed by animal testing, ECVAM organised a workshop in April 2006 to address this issue 
(Kirkland et al., 2007). The workshop focused on the possibilities to improve the current battery of in 
vitro tests in order to have a lower false positive rate resulting from the in vitro tests. This is a crucial 
step in the development of a strategy not using in vivo tests by 2009. The recommendations developed 
during the workshop are currently followed up by different groups and organisations, including 
COLIPA, ECVAM and NC3Rs. One of the recommendations was to identify chemicals that could be 
used in the evaluation of the performance of new or modified tests. Therefore, an expert panel was 
convened by ECVAM and a list of chemicals was published (Kirkland et al., 2008). These chemicals 
are now used in a project led by COLIPA and carried out by Covance (UK), which has the objective to 
improve current in vitro mammalian cell genotoxicity assays. The project addresses whether cell types, 
clones or isolates that are less susceptible to “false positive” results than others, can be identified, 
whilst still allowing the detection of all important in vivo genotoxins and DNA-reactive, mutagenic 
carcinogens. The preliminary data that have been presented at the IWGT in Basel indicate that p53 
compromised rodent cell lines over-estimate genotoxic potential in the micronucleus test. Therefore, 
IWGT suggests using p53 competent cells in in vitro micronucleus or chromosome aberration tests. 
 
Another recommendation of the ECVAM workshop was to evaluate, if the current requirements for 
testing (top concentration and highest level of toxicity) could be modified so as to reduce the number 
of “false positive” results and as such avoid unnecessary additional animal testing, whilst still allowing 
the detection of all important in vivo genotoxins and DNA-reactive, mutagenic carcinogens. To address 
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this issue ECVAM has commissioned an analysis of published data for top concentration and upper 
limit of cytotoxicity considerations in mammalian cell genotoxicity testing. The objective of the 
analysis was to determine whether concentrations as 10mM are needed to detect in vivo genotoxins 
and DNA-reactive, mutagenic carcinogens using in vitro mammalian cell tests or whether a lower level 
can be justified. The analysis suggests that about 5% of chemicals would be missed by the testing 
battery, if the top concentration was reduced to 1mM. However, a preliminary analysis shows that, 
among these chemicals, some are misleading positives and other are picked up when newly tested, 
using current testing guidelines (manuscripts are in preparation). These data have been presented at the 
IWGT, where a consensus was reached that there are reasons to reduce the 10mM top dose. This topic 
is also under discussion in the revision of the ICH guidance for genotoxicity testing and data 
interpretation for pharmaceuticals intended for human use. 
 
Another recommendation that had been made by the nominated expert sub-working group in 2005 was 
the introduction of an additional in vitro step using skin models (Maurici et al., 2005). Taking on this 
recommendation, the COLIPA Task Force Genotoxicity and ECVAM have started a study on the 
optimisation of the in vitro micronucleus, and the Comet assays in reconstructed human epidermis 
models. The optimisation and the transferability phases are now completed, and the within- and 
between-laboratory reproducibilities are currently under evaluation. 
 
ECVAM is also currently evaluating possibilities for achieving reduction in animal use. With an aim to 
evaluate reduction opportunities, ECVAM has conducted a survey to collect data on reduction 
opportunities in the Micronucleus Test in vivo and the Chromosomal Aberration Test in vivo from 
industry and CROs. The goal of this activity was to investigate current practice with regard to animal 
use (number of animals, single or both sex, use of negative and positive controls, etc). Based on the 
results of the ECVAM survey, it became clear that, although some opportunities for reduction already 
exist, they are not being implemented by everybody. The outcome of this survey served as the basis for 
the ECVAM workshop on “Reduction in Regulatory Genotoxicity Testing: Identification and 
Implementation Opportunities” which was held in June 2008.  The objectives of the Workshop were to 
evaluate: 1) how to reduce the number of animals in standard genotoxicity testing, 2) whether the 
number of animals can be reduced by applying smarter testing strategies, and 3) to brainstorm how 
these reduction possibilities can be promoted and implemented. Reduction opportunities, such as 
omission of positive and/or negative control animals, evaluation of one gender only, analysis of two 
time points in the same animal, integration of a genotoxicity assay in the 28-days repeated dose 
toxicity assay, combination of genotoxicity assays in the same animals were assessed and discussed 
(Pfuhler et al., in press).  
 
International validation studies on the comet assay in vitro and in vivo are currently ongoing under the 
coordination of JaCVAM. 
 
 
1.5 UV-INDUCED EFFECTS  
 
ACUTE PHOTOTOXICITY 
 
The validated 3T3-NRU in vitro phototoxicity test (3T3-NRU-PT) gained regulatory acceptance in 
all EU Member States in 2000 (EC, 2000) and in the OECD Member States in 2004 (OECD, 2004b). 
The test is now widely used in the chemical and cosmetic industries. 
 
Subsequently, the usefulness of reconstructed human skin model assays as a supplementary assay to 
the 3T3-NRU PTwas demonstrated in several studies (Jones et al., 2003; Lelièvre et al., 2007; Liebsch 
et al., 1995; Liebsch et al., 1997; Liebsch et al., 2005; Portes et al., 2002; Jírová et al., 2005). 
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These studies showed that a true phototoxic potential of a chemical which is correctly predicted in the 
3T3-NRU-PT may be modified and modulated when applied topically to the skin at low concentrations 
(e.g. in formulations) and additional information on phototoxicity linked to barrier function, tissue 
distribution and bioavailability of the chemical in the skin may be needed. 
 
The reconstructed human skin model assays represent a useful tool for confirmation of non-phototoxic 
and phototoxic samples identified by the 3T3 NRU PT. However, no test method was submitted to 
ECVAM yet. 
 
Further investigations are needed in the extrapolation of in vitro results to the human situation. In a 
limited study focused on a specific group of chemicals, it was shown that in certain cases, the human 
situation may be underpredicted (Kejlová et al., 2007) and a safety factor should be considered for 
extrapolation. 
 
Recently, the Safety Ad Hoc Group (SAHG) of the European Federation of Pharmaceutical Industries 
and Associations (EFPIA) commissioned a survey of member companies to understand the triggers for 
photosafety testing and how in vitro hazard characterization translated to in vivo risk. Data from 10 
EFPIA member companies relative to 361 compounds (97% of which had data for the 3T3-NRU-PT) 
indicated that the in vitro photosafety assays are over predicting animal photosafety in vivo and human 
photosafety risk in  the clinic. These findings raise concerns regarding the use of in vitro photosafety 
assays for assessment of chemical photosafety of pharmaceuticals for regulatory purposes, and further 
underline the usefulness of reconstructed human skin models as supplementary assays to the 3T3-
NRU-PT (Lynch & Wilcox, 2010). 
 
Recent research studies report the characterization of alternative cell lines and models for 
phototoxicity assessment. A study performed on L-929 cells showed that this cell line presented a 
phototoxic response similar to that of 3T3 cells, suggesting that the L-929 cell line could be a valuable 
alternative to 3T3 cells in the in vitro screening for phototoxicity assessment (Ray et al., 2008). In 
addition, a comparison study of solar radiation-induced cellular damage between ex vivo porcine skin 
organ culture and in vitro reconstructed human epidermis suggested that both cultures are good 
surrogates to human skin tissues and are relevant tools for phototoxicity studies (Bacqueville & 
Mavon, 2009). 
 
Additionally, a research paper reported the use of E. Coli as an alternative and low cost in vitro test 
system for the screening of the phototoxic potential of chemicals and cosmetic products (Verma et al., 
2008). 
 
Finally, an in vitro high-throughput cell-free assay, which monitors the generation of   reactive oxygen 
species (ROS) from test compounds by combining the use of a multiwell plate and a quartz reaction 
container was developed and assessed in-house in the laboratory that developed the test, and suggested 
to be an effective tool as a first screen to predict the phototoxic risk of chemicals (Onoue et al., 2008). 
 
New developments on acute phototoxicity were presented at the 7th World Congress on Alternatives & 
Animal Use in the Life Sciences, held in Rome on 30 August to 3 September, 2009.  
In particular, Kandárová reviewed and discussed existing findings on the potential and usefulness of 
3D reconstructed human skin equivalents to estimate phototoxic damage (Kandárová, 2009).  
In addition, the results of an in vitro phototoxicity test performed with the reconstructed human skin 
model KeraSkin™ showed high predictivity of phototoxic potential for nine chemicals, suggesting that 
KeraSkin™ could be a valuable alternative in vitro test method for phototoxicity (Ryu et al., 2009).  
 
A comparative analysis of the phototoxic predictivity of three reconstructed human skin equivalents, 
Epiderm™, KeraSkin™ and Melaskin™ was performed with 8 chemicals, showing the same results 
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and good correspondence with in vivo data for the three models, suggesting that they could efficiently 
discriminate between phototoxic and non-phototoxic chemicals (Sohn et al., 2009). 
 
Finally, an in vitro strategy for phototoxicity testing was presented based on complementary endpoints: 
(I) supercoiled circular DNA for assessment of photoreactivity, (II) yeast Saccharomyces cerevisiae 
for evaluation of photocytotoxicity and photomutagenicity, (III) use of normal cultured human skin 
cells where photogenotoxicity can be detected using the comet assay (IV) and reconstructed skin. Such 
a strategy should allow the evaluation of compounds with very different physicochemical properties 
(Marrot et al., 2009). 
 
However, all these test systems are still in the research and development phase and for most of them 
further work is needed to optimise them before they can be considered for validation by ECVAM.  
 
1.6     SKIN ABSORPTION/PENETRATION 
 
In vitro tests for the determination whether a chemical penetrates through skin were accepted at OECD 
level in 2004 (OECD, 2004c) and at EU level in 2008. In vitro methods for skin absorption measure 
the diffusion of chemicals across excised human or pig skin in flow through or static diffusion cells. 
An OECD guidance document for the conduct of skin absorption studies describes the circumstances 
in which the use of the in vitro method would be appropriate (OECD, 2004d).  
 
In 2007, preliminary results on an in vitro test based on reconstituted human epidermis (RhE) models 
were submitted to ECVAM for evaluation. The advantages of this test method are the adequate 
availability of RhE models, the shorter duration of the experiments and possibly also the investigation 
of skin metabolism in skin tissue of human origin (Schäfer-Korting et al., 2006). Another important 
advantage is the much lower variability in results due to standardized production of the RHE models 
when compared to the results obtained with excised skin, as was demonstrated in the European FP5 
EDETOX project (http://www.ncl.ac.uk/edetox/abouttheedetoxproject.html, van der Sandt et al., 
2004).  
Furthermore, by introducing skin models also for skin absorption, beside skin corrosion and skin 
irritation, would allow comparing results for specific chemicals across endpoints more easily.  
 
In 2008, the performance of RhE models for the determination of skin absorption was further 
evaluated by testing nine substances, covering a wider range of physico-chemical properties, in ten 
laboratories under strictly controlled conditions (Schäfer-Korting et al., 2008). The results showed that 
the permeation properties of RHE exceeded that of human epidermis and pig skin, yet the ranking of 
substance permeation through RHE models reflected the permeation through human epidermis. RHE 
models showed lower variability of data and sufficient correlation between all preparations examined. 
Thus, RHE models seem appropriate alternatives to human and pig skin for in vitro assessment of 
permeation and penetration of substances. An expanded substance panel and an increase in the number 
of experiments are needed to progress the assay through validation. 
 
Recent studies report the development of a modified growth method for cultured skin substitutes. 
These skin substitutes, developed under anchored conditions, were shown to present better barrier 
properties than those grown by standard methods, thus being more suitable as an in vitro skin 
permeability model (Barai et al., 2008). 
 
In addition, recent studies report the development of a predictive model for estimating the cumulative 
mass of a chemical absorbed into and across the skin from cosmetic/dermatological formulations, 
which could provide a tool for assessment of in vitro permeation (Gregoire et al., 2009).  
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Here again, all these test systems are still in the research and development phase and for most of them 
further work is needed to optimise them before they can be considered for validation by ECVAM. 
 
2. HUMAN HEALTH EFFECTS FALLING UNDER THE 2013 
 DEADLINE 
 
2.1 SKIN SENSITISATION 
 
The assessment of the skin sensitisation potential of chemicals still relies on the use of animals due to 
the lack of validated partial replacement or full replacement methods. It is increasingly aknowledged 
that the complexity of the mechanisms underlying this human health effect will require the 
combination of in silico, in chemico and in vitro approaches to ensure the safe use of products. 
 
At research level, ECVAM is strongly involved in the EU FP6 Integrated Project “Sens-it-iv” (2005-
2010) (http://www.sens-it-iv.eu) which aims to contribute to the replacement of animal 
experimentation by in vitro assays for identifying skin and respiratory sensitisers in relation with the 
use of safe ingredients by the chemical, cosmetic and pharmaceutical industries. In October 2008, the 
Annual General Assembly of the project constituted an important milestone for the project, since it 
marked the passage from the science to the technology module in which more emphasis will be given 
to test methods development rather than research. A number of promising in vitro methods and 
biomarkers are currently under investigation for their potential to discriminate a) between sensitisers 
and irritants b) between respiratory and skin sensitisers, with the ultimate goal to combine them into a 
testing strategy able to deliver information on potency. ECVAM is providing support in order to bring 
these methods up to a level of development/standardisation which comply with its criteria for entering 
prevalidation.   
 
With regard to validation activities, three partial replacement tests, namely the Direct Peptide 
Reactivity Assay (DPRA), 2) the human Cell Line Activation Test (h-CLAT) and 3) the Myeloid U939 
Skin Sensitisation Test (MUSST), have been formally submitted to ECVAM. These tests, developed 
by Colipa associated Industries, underwent extensive optimisation through ring trials within Colipa. 
Further to the evaluation by ECVAM, the tests entered phase III of a prevalidation study in which the 
laboratory reproducibility and the preliminary predictive capacity will be assessed with a set of coded 
chemicals. It is envisaged that these tests, once formally assessed for their reliability, may play a role 
as building blocks in a future testing strategy for the full replacement of current animal tests. 
Consideration is also given to the availability of validated non-radioactive modifications of the LLNA 
to improve its regulatory use that would imply further reduction in the number of animals used for the 
assessment of the skin sensitization potential of chemicals. To be able to properly assess such variants 
of the standard LLNA, and on the basis of the recommendation of an ECVAM workshop on: “An 
Evaluation of Performance Standards and Non-radioactive Endpoints for the Local Lymph Node 
Assay” (Basketter et al., 2008) ECVAM has been working in close collaboration with ICCVAM on 
the development of a harmonized set of Performance Standards (PS) for the LLNA. The ECVAM 
harmonised PS for the LLNA were endorsed as scientifically valid by ESAC during its 29th meeting 
(ESAC, 2008b). The inclusion of the harmonised PS in the proposed revision of the OECD TG 429 is 
currently on-going. 
In addition, the reduced Local-Lymph Node Assay which uses fewer animals than the tradional 
LLNA is also being included in the revised OECD TG 429. The reduced LLNA was validated by 
ECVAM and was endorsed as scientifically valid by the ESAC during its 26th meeting (ESAC 2007c).  
 
In the field of respiratory sensitisation, an expert meeting was convened at ECVAM in April 2008 
(Roggen et al., 2008) to consider what progress has been made in the light of the recommenations 
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derived from the 2006 Workshop and the published report (Kimber et al., 2007) and to explore how 
advances in the development of methods for the identification of skin sensitising chemicals could be 
exploited for the evaluation of chemical respiratory allergens. The workshop participants concluded 
that beside some progress in the QSAR field, little progress has been made since the previous 
workshop. This is mainly attributable to the lack of a generally accepted animal model, the complexity 
of the lung and the yet poorly understood underlying biological mechanisms. Therefore, research is 
still needed to fill these gaps. Among the current activities in the area of skin sensitisation which could 
be exploited also in the field of respiratory sensitisation it was suggested that the Peptide Binding-
Assay, DC-based assay and the LLNA may provide useful tools to identify respiratory sensitisation 
hazard. However, there remains the need for additional work to determine whether these methods can 
reliably discriminate between skin and respiratory sensitisers. 
 
2.2 SUBACUTE AND SUBCHRONIC TOXICITY  
 
ECVAM was involved in the European STREP project PREDICTOMICS 
(http://www.predictomics.com/) that aimed at developing a novel platform for anticipating liver and 
kidney chronic toxicity elicited by drugs and xenobiotics. The final goal was to identify specific early 
mechanistic markers of toxin induced cell alterations by integrating genomic, proteomic and cytomic 
analysis. The project ended in December 2007 and the main achievements were the following 
(http://www.predictomics.com/): 
 
1. Revised version of gene expression fingerprint profile for steatosis induced in cell cultures. 
2. Development of an assay based on HepG2 cells to detect steatosic potential of drugs using a 
multiparametric flow cytometry approach. 
3. Development of a high-content assay based on bioimaging to detect steatosic potential of drugs 
by using a multiparametric image analysis approach. 
4. A prediction model for steatosis based on transcriptomic profiles and cytomic analysis, in the 
course for being prevalidated. 
5. Development of several new fluorescent bile-acid probes to investigate interference in bile-acid 
transport by drugs. 
6. Development of flow cytometric kinetic assays suitable to follow on real time the uptake and 
efflux of bile-acid fluorescent derivatives and the interference of xenobiotics on these 
processes. A prediction model for cholestasis based on cytomic analysis has been developed, in 
the course for being prevalidated (Rohacova et al., 2008; Rohacova et al., 2009). 
7. The impact of microvascular endothelial cells on proximal tubular endothelial cells has been 
further delineated, thus providing a very well characterised renal co-culture model. 
8. Microarray analysis has been carried out for twelve nephrotoxins in Human Kidney (HK)-2 
cells. 
9. Mechanistic information on several nephrotoxins has been provided. A number of pathways 
indicative of toxicity or protection against damage have been identified e.g. the p53 pathway 
(senescence and cancer) and the Nrf2 (Nuclear factor-erythroid 2-related factor 2) pathway 
(oxidative stress). Additionally pathways involved in CsA (cyclosporine A) induced epithelial 
mesenchymal transition (EMT) have been uncovered (Jennings et al., 2009). 
10. Standard operating procedures for HK-2 cell culture, treatment and microarray analysis have 
been produced under the supervision of ECVAM. 
11. A list of markers with potential value in detecting renal injury has been generated. 
12. A preliminary prediction model for nephrotoxicity based on transcriptomic profiles has been 
developed. 
 
In summary, two in vitro models were developed to study steatosis and cholestasis (main drug-induced 
liver diseases) using model cholestatic and steatotic hepatotoxins (Gomez-Lechon et al., 2007). 
Models were also challenged with five coded drugs. A human proximal tubule model (HK-2 cells) has 
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been established for the purposes of conducting gene expression microarrays with the Affymetrix 
HGU-133 plus 2 platform. Using 12 nephrotoxic compounds, a number of marker genes have been 
identified which are potential markers of early response to toxicity.  
 
At OECD level, the revision of OECD test guideline on chronic in vivo toxicity studies (TG 452) took 
place during 2008 and is still under discussion at the OECD WNT. 
 
In the field of immunotoxicity, a study to prevalidate a set of in vitro assays was finalised in April 
2008. Human Peripheral Blood Mononuclear Cells (PBMC), murine, or rat splenocytes were used. For 
each of the three species, basal cytotoxicity was assessed before commencing the tests using the LDH-
release endpoint. Human PBMC were stimulated with anti-CD3/anti-CD28, murine splenocytes with 
anti-CD3/anti-CD28, concanavalin A (Con A), lipopolysaccharide (LPS), and anti-CD40/IL-4, and rat 
splenocytes with Con A and LPS. Cell proliferation and production of IFN-γ and TNF-α were taken as 
endpoints. Seven compounds, for which good human and/or animal data are available, were selected: 
six with well-known effects on the immune system (benzo(a)pyrene (BaP), cyclophosphamide (CY), 
methotrexate, rapamycin (RAP), dexamethasone (DEX), and urethane) and one chemical classified as 
non-immunotoxic (D-mannitol). Each species/stimulant/endpoint combination was evaluated by using 
criteria of fold-stimulation and threshold levels for proliferation and cytokine production. For 10 of the 
21 combinations tested, these criteria were met, and they were evaluated for their ability to identify 
immunosuppressive activity. 
The percentage of correct predictions of immunosuppressive activity was established by using criteria 
of suppressed response. This prediction was made using the results of all 10 species/stimulant/endpoint 
combinations. Five out of 6 positive compounds could be identified as immunosuppressive (correct 
prediction >30%) and the non-immunotoxic compound came out as negative. These results suggest 
that in vitro assays are able to detect immunosuppression, holding promise for further evaluating these 
assays using a wide range of chemicals. 
 
Further to two ECVAM workshops on chronic toxicity and physiology-based pharmacokinetic 
modeling (PBPK), a FP7 collaborative project Predict-IV started in May 2008. This project addresses 
strategies to improve the assessment of drug safety in the early stage of development and late 
discovery phase, by an intelligent combination of non animal-based test systems, cell biology, 
mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. The aim is to 
identify general pathways resulting in toxicity that are independent of cell/tissue type. Metabonomics, 
high content imaging and other endpoints capturing deregulation of essential cellular processes will be 
combined to develop a testing strategy with predictive capacity (http://www.predict-iv.toxi.uni-
wuerzburg.de/).  
The three main target organs under investigation are the liver, the kidney and the Central Nervous 
System. The activities are relevant to other fields beside drug development, such as the prediction of 
repeated dose toxicity of cosmetic ingredients. 
 
During 2008, a COLIPA-DG RTD Joint Research Inititiative has been established and has resulted 
into a new FP7 call in 2009, focusing on repeated dose toxicity. The ultimate long-term goal is the 
replacement of repeated dose toxicity testing in human safety assessment. 
 
2.3 TOXICOKINETICS AND METABOLISM 
 
Toxicokinetics and metabolism are of importance for most of the other toxicological endpoints and 
considered as a crucial aspect for the predictivity of alternative tests.  The complexity of physiological 
regulations and impact networks within a living animal will require tiered approaches and integrated 
testing strategies to answer all questions related to systemic toxicities. The details for an approach 
specifically relevant for cosmetics are outlined in Coecke et al. (2005). Details are given below on how 
the different information sources can be gathered to carry out both, quantitative and qualitative 
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evaluations of toxicity, based on a tiered approach including toxicokinetic and metabolism 
information, and as follow-up to the recommendations made in 2005 (Coecke et al., 2005). 
 
2.3.1  Barrier models  
ECVAM was involved in the studies of absorption barrier models. In particular, an ECVAM 
prevalidation study on in vitro models for the prediction of gastro-intestinal absorption was finalised in 
2008 and a publication of the outcome of the study is in preparation (Prieto et al., submitted). Ten test 
chemicals for which in vivo oral absorption data are available were tested in two laboratories. 
Atenolol, cimetidine and propranolol were included as reference compounds for low, medium and high 
intestinal absorption, respectively. Transport experiments were independently carried out in the two 
laboratories. Median CVs of 10.5% and 15.5% were found for each laboratory. Concerning between-
laboratory reproducibility, comparable response levels were found for the three references compounds 
and for paracetamol while, for the other chemicals, lower reproducibility was obtained, in particular 
for those actively transported. No significant differences in Papp values were reported between the two 
cell lines investigated. Due to the limited number of chemicals tested, a model with a real predictive 
value in terms of in vivo absorption is not realistic; nevertheless a preliminary prediction model has 
been established using two mathematical models available from the literature. Good in vitro-in vivo 
correlation was obtained for well absorbed compounds, while moderate and low absorbed compounds 
were rather overestimated. Both Caco-2 models were more reliable to identify compounds that use 
passive diffusion than active transport to cross the gastro-intestinal barrier (since Caco-2 cells under- 
or overexpress only some of the transporters present in the intestinal mucosa), and for skin barrier 
(alternative tests for percutaneous absorption were adopted as OECD Test Guidelines in 2004; see 1.6 
above). The data generated by such models are crucial input into more global kinetic models used to 
predict the fate of chemicals in vivo. The feasibility study to evaluate the performance of five selected 
in vitro blood-brain barrier (BBB) models for predicting the uptake into the brain was finalised in 
2008. Overall, the results of the ECVAM study point out that the new in vitro BBB model (4d/24w), 
suitable to automation (Culot et al., 2008), constitute an opportunity to considerably increase the rate 
at which BBB permeability data can be generated. In addition, the combination of this in vitro BBB 
model (4d/24w) with SHSY5Y neuroblastoma cells as target cells, represents a convenient approach to 
explore the importance of the BBB in neurotoxicity assessment. (Hallier-Vanuxeem et al., 2009). In 
collaboration with Sovicell GmbH, ECVAM is evaluating a hybrid system that combines an in vitro/in 
silico model. Results are being generated with the same set of 16 compounds and will be compared 
with the permeability data obtained in the ECVAM BBB study with the 5 different in vitro models.  
 
2.3.2  Biotransformation 
 
Metabolism (biotransformation) plays in many cases a key role in the origin of toxic effects and is also 
critical when evaluating inter and intra-species differences. Toxic effects can also be increased through 
processes which impact the metabolic capacity of systems. Therefore, it is also important to have alerts 
when some compounds have critical effects on the overall metabolic capacities of cellular system by 
inducing it (Coecke et al. 1999), inhibiting it, or by direct metabolism-mediated cytotoxic effects 
(Coecke et al. 2006; Jacobs et al., 2008).   
 
Most of the in vitro systems are lacking metabolising capacities and this has been recognised as being 
a bottle-neck in in vitro test development. A strategic approach to have an indication of the likelihood 
that metabolism-mediated effects play a role is by trying to combine in vitro systems with a metabolic 
competent source (i.e. a system that models hepatic biotransformation. Alternatively, in a tiered 
approach (Coecke et. al, 2005), an indication of metabolism-mediated toxicity can alert and lead to 
specific decision points when assessing systemic effects. 
 
Exposure to drugs, occupational and industrial chemicals, or environmental pollutants, can lead to 
either the induction or the inhibition of biotransformation. Due to susceptibility of Cytochrome P450 
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(CYP) to being induced, i.e. increases in enzymatically active microsomal protein content after 
exposure to specific chemicals, these enzymatic systems have been shown to be involved in various 
side effects, such as profound endogenous hormonal disturbances, increased liver weight, drug-drug 
interactions and exacerbated toxic effects. Therefore, routine evaluation of the inducing potential of a 
given chemical on these pathways is essential for human safety assessment (Coecke et al., 1999, 
Coecke et al. 2006). Expert teams on metabolism, toxicokinetics and induction were established to 
further the developments in the field of toxicokinetics and metabolism with an aim to validate the 
necessary test systems.  
 
The prevalidation on the applied use of freshly isolated human hepatocyte cultures, assessed by 
looking at the predictive capacity for liver enzyme induction involving three independent laboratories, 
was completed. The corresponding report is being finalised and submitted. 
On 4-5 September 2008, ECVAM organised a stakeholder meeting in the field of Toxicokinetics and 
Metabolism. During this stakeholder meeting, all participants agreed that a validation study that would 
provide a standard for human hepatic metabolism and toxicity would be very beneficial. In order to 
approach this question, initially the potential for cytochrome P450 (CYP) induction at doses which are 
of clinical relevance applied to the in vitro systems will be assessed. The CYP enzymes are known to 
be the predominant enzymes involved in metabolism and toxicity as compared to other 
biotransformation enzymes. Therefore, the assessment of the presence of different CYP isoforms is an 
essential part of metabolic competence assessment.  Induction has a complex underlying mechanism 
(gene activation followed by de novo protein synthesis) and for this reason, it is a good indicator for 
high quality metabolic competent systems that can be used long-term. The results of this study are 
envisaged to be the starting point for a novel in vitro platform for assessing metabolism and toxicity. 
 
Two human hepatic metabolic competent test systems are under evaluation: the HepaRG test system 
and cryopreserved human hepatocytes. For both test systems a test method has been established for the 
determination of CYP activities in HepaRG cells cultured in 96-well plates and in cryopreserved 
human hepatocytes cultured in 48-well plates. The endpoint “induction of CYPs” is measured after 48 
hours in the HepaRG test system, and after 72 hours in the human cryopreserved hepatocytes, 
following treatment with test compounds and two reference compounds (β-naphthoflavone and 
rifampicin), using a cocktail of prototypical substrates for different CYP isoforms incubated directly 
with the two test systems. Phenacetin, midazolam, bupropion and diclofenac will be used as probe 
substrates present in the cocktail to evaluate the induction of CYP1A2, CYP3A4/5, CYP2B6 and 
CYP2C9, respectively. ECVAM is practically participating with its own laboratoratories in this study. 
 
A comparative study of rat and human in vitro metabolising systems (microsomes versus 
homogenates) on a set of chemical compounds is completed.   The goals of the project were to 
characterise, with human and rat liver homogenate or microsomal preparations, the metabolic stability 
(i.e. disappearance of the parent substance from incubations with human liver preparations and 
appropriate cofactors for metabolism) and the appearance of metabolic products and their tentative 
identification. Using this approach important background information was gained for characterising 
the studied substances in order to predict, in the end, their behaviour in the in vivo situation. Equally 
important is that the data obtained illustrate similarities, but also quantitative and qualitative 
differences between homogenate and microsomes, as well as between human and rat. The basic 
approach suits equally well for the characterization of metabolic capability of any tissues or cell 
cultures from various animals. A follow-up study to assess the same 55 compounds in the above 
described human metabolic competent test system is planned. The results of this study have served in 
the process of drafting a new test guideline for the 2-generation reproductive toxicity study by 
introducing in the guideline different paragraphs related to toxicokinetics and metabolism including a 
specific mentioning of the need to assess in vitro metabolic processes to assess species differences  
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2.3.3  Physiologically-based pharmacokinetic modelling (PBPK) 
 
An ECVAM workshop report on Physiologically-based Kinetic Modelling (PBK): Meeting the 3Rs 
Agenda (Bouvier d’Yvoire et al., 2007) describes the strategy proposed by the participants to: 
- to better define the potential role of PBK modelling, as a set of techniques capable of 
contributing to the reduction, refinement and replacement of the use of  laboratory animals 
in the risk assessment process of potentially toxic chemicals; 
- to discuss the need for technical improvement in PBK modelling and its applications; and 
- to identify the need to increase understanding and, potentially, acceptance by the regulatory 
authorities, of the capabilities and limitations of PBK modelling techniques in toxicological 
risk assessment. 
 
It furthermore also intended to provide the non-expert reader with an overview of the field in relation 
to the Three Rs, with some key references. 
 
As a follow-up to the tiered strategy proposed by the Toxicokinetic and Metabolism expert panel 
(Coecke et al., 2005) focussing on Cosmetics, the practical use of PBK models has been discussed at a 
recent meeting on Toxicokinetics and Metabolism held on 4-5 March 2009. One of the very interesting 
PBPK Model Equation Generators called MEGen developed at the Health and Safety Laboratory is 
currently being reviewed by ECVAM (Loizou et al., 2008; Loizou, 2009).  Necessary steps need to be 
undertaken to adapt MEGen to the needs related to the toxicological requirements of the Cosmetic 
Directive.  
 
ECVAM commissioned to RIVM the development of a pilot database with kinetic parameters of 
compounds used as reference substances in various in vitro toxicity testing (pre)validation 
programmes. The toxicokinetic properties of compounds can form valuable information in human risk 
assessment. In vivo as well as in vitro, biological targets are exposed to concentrations of the 
compounds or their metabolites. Concentrations and their time course, mostly determined in blood or 
plasma, provide the most direct link between the observed or predicted in vivo effects and the effects 
observed in vitro. Accurate quantitative knowledge of the in vivo concentration-time relationship is 
therefore a prerequisite for the correct interpretation of in vitro toxicity testing results. Classical 
compartmental modelling parameters were chosen to describe the in vivo kinetic properties as they 
fulfil the needs for prediction of in vivo concentration time profiles under linear conditions. Protein 
binding parameters were added to facilitate calculation such as unbound substance concentrations. 
Beside an input module (storage template) for the database, a retrieval template was developed to be 
put on the ECVAM website to facilitate further use of kinetic data. The database was filled with 
human and rat kinetic parameters (mainly based on intravenous and oral administration) for 100 
substances following assessment of their reliability. Kinetic data 
were collected on classical compartmental modelling parameters, which describe the absorption, 
distribution and elimination (metabolism and excretion) phase. Typical classicalcompartmental 
modelling parameters are systemic bioavailability, absorption rate constant, volume of distribution and 
elimination rate constant. This pilot database contains kinetic parameters for internal exposure 
estimation, which may facilitate quantitative in vitro- in vivo extrapolation and will be essential data in 
PBK efforts.  
   
2.4 CARCINOGENICITY 
 
The cell transformation assay (CTA) was identified, beside the gap junction communication assay 
(GJIC), as the only available in vitro carcinogenicity assay. In 2007, the OECD published a Detailed 
Review Paper (DRP) on the CTAs (OECD, 2007). The DRP concluded that, based on the available 
data, the performances of the SHE and the Balb/c 3T3 CTAs were considered adequate for 
recommending that they are included into official OECD Test Guidelines. Using the draft DRP as a 
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basis, and following the recommendations of a previous workshop (Combes et al., 1999), and an 
expert meeting on cell transformation held at ECVAM in 2004, it became clear that a formal validation 
of the assays, in particular focusing on the reproducibility and the development of a standardised 
protocol, were needed. Consequently, ECVAM coordinated and sponsored a prevalidation study of 
CTA in both SHE (pH 6.7) and Balb/c 3T3 cells. Due to promising preliminary results, the 
prevalidation of a third variant of the assay (SHE pH 7.0) was initiated in January 2008. The aim of 
this prevalidation study was to assess the reproducibility of these three standardised protocols. In order 
to evaluate whether the tests would meet the criteria requested by the ECVAM principles on test 
validity, the modular approach of validation was followed (Hartung et al., 2004). In this study four 
modules were fully assessed:  1) test definition, 2) within-laboratory reproducibility, 3) transferability 
and, 4) between-laboratory reproducibility. In addition, the data generated add to the understanding of 
the predictive capacity of the CTA, which was previously addressed by the OECD DRP evaluation 
(OECD, 2007). Each in vitro test was conducted according to the same agreed protocol in three 
different laboratories. The evaluation of the results on the reproducibility of the three assay variants 
was completed and the prevalidation reports were prepared with the intention to be submitted to an 
ESAC peer review panel for a final assessment of the scientific validity of the cell transformation 
assays in accordance to modules 1-4. The outcome of the study will be published in a special issue of 
Mutation Research (in preparation). 
 
A new variant of the CTA based on a derived Balb/c 3T3 clone, Bhas 42, is under validation by 
JaCVAM and ECVAM is involved in the Validation Management Team. 
 
Besides the CTA, the use of toxicogenomics-based tests is being explored in collaboration with 
external partners. Furthermore, the FP6 Integrated Project CARCINOGENOMICS was initiated and 
aims at developing in vitro methods predictive for carcinogenicity in major target organs, i.e. liver, 
lung and kidney. In the frame of the CARCINOGENOMICS project, several initiatives were taken to 
involve regulators in the discussions on the conditions that newly developed methods have to meet for 
regulatory acceptance in the area of carcinogenicity testing. Among these, a workshop on Genomics in 
Cancer Risk Assessment was organised last August 27-28th in Venice, as a satellite symposium of the 
7th World Congress on Alternatives and Animal Use held in Rome. The state-of-the-art in chemical 
cancer risk assessment was explored and the possible contribution of genomics and systems toxicology 
with respect to tackling the current flaws and uncertainties was discussed. Most importantly, the 
workshop was successful in bringing together leading experts from academia, industry and regulatory 
authorities for this and in identifying the road lying ahead: by taking the systems toxicology approach, 
generating mechanistic information on toxic responses from bioassays consisting of human cells, and 
linking this with growing insights in molecular processes underlying human pathophysiologies. 
 
2.5 REPRODUCTIVE AND DEVELOPMENTAL TOXICITY 
 
2.5.1 Sixth EU framework programme integrated project “REPROTECT” 
 
Due to the high impact of reproductive toxicity studies on the number of animals used for the detection 
of reproductive and developmental toxicants, ECVAM drafted and initiated an integrated project 
called “ReProTect” with the aim to stimulate further development and optimization of in vitro models 
for toxicological safety testing in this area (http://www.reprotect.eu/). Several tests mentioned in the 
Cosmetics Report (Bremer et al., 2005) have been included in order to make them available for 
entering the validation process. ECVAM is providing scientific/technical support to the project 
coordinator as well as relevant information on the development of testing strategies. Moreover, 
ECVAM sponsored the statistical analysis of the data produced in order to evaluate the within- and 
between-laboratory variabilities of the developed/optimised assays and will host the project database 
after the project’s effective end. Importantly, the project delivered a test battery of 14 successfully 
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developed in vitro tests, which have been challenged with 10 compounds under blind conditions. The 
predictive outcome was quite impressive and a manuscript has been accepted for publication. 
 
Several tests will be presented in a special issue of the journal Reproductive Toxicology that will be 
ready in 2010. 
 
ECVAM received submission of test methods which assess the capacity of test chemicals to influence 
hormonal pathways. 
 
Research Area “Fertility”: 
 
• Computer-assisted sperm analysis as a building block in a testing strategy to replace 
one/two generation studies (OECD TGs 415 and 416) (W.P. I.1). This test was optimised 
and successfully transferred to a second laboratory. More than 40 chemicals were analysed for 
their effects on sperm motility. An independent statistical evaluation demonstrated the 
reliability and transferability of the test between two laboratories. A formal validation study 
will be considered. However, a first expert review noticed that the IC50 values were extremely 
high. A further evaluation to consider the relevance of the test in testing strategies is necessary. 
 
• Cell lines employed in studies on steroidogenesis. A genetically engineered BLT1 Leydig 
tumor cell line was developed within ReProTect. Several chemicals were tested in one 
laboratory using the new genetically engineered cell line. SOPs using BLT1-L17 cells as a tool 
for a Leydig cell toxicity test are available. The statistical evaluation is currently taking place 
and if the results are promising, a decision on the formal validation of the test will be taken.  
 
• Sertoli cell lines. The establishment of SOPs for the Sertoli cell line SerW3, as well as for the 
primary cells was finalised and 10 test chemicals were evaluated in two independent 
laboratories. The data are now analysed by an independent statistician in order to decide on 
further validation. However, due to the internal reorganization of the responsible ReProTect 
partner that has participated in the study, follow-up studies could not be foreseen.  
 
• The follicle culture bioassay (FBA), Mouse/Bovine oocytes as building blocks in a testing 
strategy to replace one/two generation studies (OECD TGs 415 and 416) Granulosa/Thecal 
cells (W.P. I.5) and Folliculogenesis (W.P. I.6).  
The test development for oocytes bovine maturation (IVM)/fertilization (IVF) and pre-
implantation embryo (IVP) was concluded by producing the SOP and by testing 16 chemicals. 
The evaluation of the transferability of the IVM test was planned. The transferability and the 
evaluation of the within-laboratory variability will be published in the special issue of 
Reproductive Toxicology. 
Twenty-six compounds were tested under the developed mouse oocytes assay’s (MEA) SOP 
and the statistical analysis of the data generated is ongoing. SOPs are now available for the 
detection of adverse effects on steroidogenesis. For the follicle culture bioassay (FBA), the raw 
data generated after testing more than 20 well-known chemicals were transferred to the 
appointed statistician. The final report and the submission of a scientific manuscript are 
planned. The development of the Granulosa test is concluded. Unfortunately, the statistical 
analysis revealed a high within-laboratory variability of the test, most probably due to the 
instability of the genetically engineered cells developed.  
 
Research Area “Implantation”: 
 
• Endometrium/implantation and oviduct studies (W.P. II.1)  
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The main objective of the WP is to establish cell culture models and explants specific for 
composing the endometrium. Two targets were considered: the human endometrial endothelial 
and stromal cells. Moreover, it has been planned to detect estrogen receptor, apoptosis markers 
of oxidative stress and cell death, drug metabolising cytochrome P450 and drug transporters on 
the target cells.   
Preliminary SOPs for human endometrial stromal/endothelial cells are prepared but a delay in 
the work planned has to be expected due to the inconsistency of the scientific results. The 
development of a test based on the use of the human endometrial explants and cell lines is 
ongoing. The SOPs were established and the definition of the most predictive endpoints was 
carried out. Moreover, the testing phase has already started with few selected compounds and 
the data generated were sent to the statistician.  
 
• Placental toxicity 
The identification of important cell types in the process of placentation is ongoing. 
Furthermore, the placenta is also considered a valuable organ for studies of fetal exposure by 
the placenta perfusion. Two laboratories are currently involved in the transferability study of 
placental perfusion and some chemicals were already tested. In order to study the transport of 
cells derived from placenta, the establishment of the BeWo cell system is under evaluation. The 
SOPs for culturing and treatment of throphoblast-like cell lines and chorionic villous explants 
were delivered. The testing phase is already initiated with some selected compounds and it is 
planned to test additional substances in order to evaluate the within-laboratory variability of the 
assays. 
• The development of an in vitro system based on the use of pericyte cells is 
      ongoing and the SOP was delivered. Few compounds have been already tested   
      in order tocontinue with the test optimisation. 
 
Research Area “Prenatal development”: 
 
• Early embryonic development: The embryonic stem cell test (EST), the  
      use of human embryonic stem cells (hESC) for embryotoxicity studies and   
      the proteome signature for toxicology studies  
The differentiation of murine embryonic into neural cells was characterised by analysis of the 
neuron-specific marker. Differentiation protocols for dose-response profiles are available and 
are being challenged with selected reference compounds. Furthermore, murine embryonic stem 
cells were successfully differentiated into chondrocytes, which are another target tissue for 
teratogenic compounds. However, when the validated EST was challenged with various 
embryotoxicants, the test demonstrated a high rate of underprediction. The applicability 
domain of the test requires careful definition. The inclusion in the project of the validated EST 
was performed in order to extend the existing chemicals database by testing another 13 well-
defined substances and consequently, better define the applicability domain for the assay. Due 
to the misclassification of the tested compounds by the EST, it was decided to organise a joint 
workshop between ECVAM and ReProTect in order to bring together European scientists from 
industry and academia actively working with the EST, and to discuss the present status of the 
various derivates of the validated embryonic stem cell test. The aim was to identify how much 
flexibility could be introduced for in vitro tests based on embryonic stem cells. The workshop 
also aimed to critically review the mode of action in order to better describe the applicability 
domain of the EST (Marx-Stoelting et al., 2009).  
 
In order to identify toxicological signatures of developmental toxicants at proteome level, 
lysates of murine embryonic stem cells differentiated into cardiomyocytes (treated with 
valproic acid, diphenylhydantoin and lithium chloride) were analysed for changes in their 
proteome. Protein biomarker signatures from mESC (mouse embryonic stem cells) 
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differentiated into cardiomyocytes, and hESC differentiated into neurons, are now available, 
and the results will be published soon. 
 
• Late prenatal development  
The objective of this work is the introduction of a metabolic incubation system into the 
validated WEC (Whole Embryo Culture). The inclusion of a metabolic competent system into 
WEC was concluded by testing few chemicals under the developed SOP. 
 
Research Area “Cross-Cutting technologies”: 
 
• Quantitative Structure/Activity Relationships (QSARs) 
The development of QSARs focused on the blood testis barrier, thus complementing and 
supporting the building blocks: Leydig cells, Sertoli cells and spermatogenesis. In addition, the 
development of QSAR models for placental transfer and steroid receptor 
binding/transactivation was planned. The planned work for the QSARs activities in the project 
was concluded. QSARs model for metabolic activation, endocrine disruptor and placental 
barrier are now available within the project. 
 
• Biotransformation  
In the ReProTect project, it was planned to study the possibility to define a metabolic 
competent system that can work in conjunction with in vitro tests developed/optimised in 
ReProTect. The tasks related to this topic focused on the development of a system based on the 
use of hepatocytes able to work in conjunction with the validated embryonic stem cell test. The 
SOP is now ready, but only two compounds were tested. In order to evaluate the robustness of 
the developed protocol, more experiments should be performed.   
 
• Estrogen/Androgen receptor binding assays, which could be used as building blocks to 
replace the uterotrophic test and the Hershberger test (OECD draft TG) and one/two 
generation studies (OECD TGs 415 and 416) 
ECVAM has followed the recommendations of the ICCVAM/NICEATM report on the status 
of in vitro methods for detecting endocrine disrupting functions of chemicals (ICCVAM-
NICEATM, 2002). Four transcriptional tests (PALM, MELN, ER-CALUX®, AR-CALUX®) 
and two receptor binding assays based on recombinant proteins were selected by the ECVAM 
Task Force on Endocrine Disruption. The optimisation of the tests mentioned above, was 
finalised and the tests are currently analysed by an independent biostatistician. The data 
analysis will decide if a formal validation study should be initiated. However, the MELN, as 
well as the ER-CALUX system, are both already mentioned in the OECD performance-based 
guideline for the testing of chemicals: “Stably transfected Transcriptional Activation (TA) 
assay for the detection of estrogenic (agonist and antagonist) activity of chemicals”, which is 
delivered to the WNT as background document. ReProTect has successfully delivered the 
MELN test which is able to detect estrogenic and anti-estrogenic compounds. The test has been 
submitted to ECVAM for validation. 
Due to the good performance of the Pan Vera receptor binding test, optimised within the 
ReProTect project, a formal validation exercise under the lead of the US EPA, has started. A 
Standard Project Submission Form on Human Recombinant Estrogen Receptor Alpha Binding 
Assays was submitted to the OECD in September 2007. ECVAM has funded a participating 
European laboratory and is currently working out the data transfer to the US EPA. 
 
ECVAM is participating with its own laboratories in the LUMICELL validation study. 
LUMICELL is able to detect (anti)-estrogenic compounds. The validation study is led by 
ICCVAM, and JACVAM is also participating. The experimental phase is now finalised, the 
results are being analysed and a peer review is in preparation 
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Another in vitro test assessing estrogenic activity, the stably transfected human estrogen 
receptor-α transcriptional activation assay for detection of estrogenic agonist-activity of 
chemicals (STTA), has been adopted by OECD Council on 7 September 2009 and is now 
available as OECD TG 455. ECVAM has been in the peer review panel of the validation study. 
 
2.5.2 Other activities 
 
Due to a high number of animals needed for assessing reproductive toxicity only for the 
implementation of REACH, ECVAM also held a workshop in September 2006, on possible refinement 
methods for reproductive toxicity, which could significantly reduce the number of animals used. The 
most promising approach identified at the workshop was the extended one-generation study proposed 
by ILSI-HESI in order to evaluate agrochemicals (Cooper et al. 2006). The workshop analysed the 
study design of the extended F1 generation study for its suitability to assess also industrial chemicals. 
It was felt that with the introduction of a trigger concept this reduction/refinement method will 
significantly contribute to the reduction of animals for reproductive toxicity safety assessments, since 
the added value of the second generation seems to be very limited. Nevertheless the discussion is still 
ongoing. In addition, the relevance of developmental toxicity in a second species was questioned and 
would require further investments into retrospective validation exercises.  
 
ECVAM organised a workshop on cardiotoxicity in order to discuss possibilities to reduce the number 
of animals for cardiotoxicity assessment, but also to increase the predictive capacity of existing 
methods. The workshop report was published in September 2009 (Stummann et al., 2009).The experts 
came to the conclusion that alternative methods assessing cardiomyopathy, i.e. contractility toxicity, 
ischaemia toxicity, secondary cardiotoxicity and valve toxicity are at a nascent stage. Alternative tests 
in the field of drug-induced arrhythmia are relatively advanced, but are mainly performed in addition 
to in vivo studies with the aim to improve drug safety and are focusing strongly on hERG blockage or 
QT prolongations. Prediction of proarrhythmic potential in humans could probably be improved by 
including alternative assays (in silico or in vitro) covering additional mechanisms of the arrhythmic 
toxicities.  
 
 
3. NON-TESTING METHODS 
 
Non-testing methods include qualitative and quantitative structure-activity relationship models (SARs 
and QSARs; collectively referred to as (Q)SARs), as well as less formalised chemical grouping 
methods that form the basis of chemical category and read-across approaches. All of these methods are 
based on the premise that the properties (including toxicological activities) of a chemical can be 
directly predicted from its molecular structure or inferred from the properties of similar compounds 
whose activities are known. The concepts and applications of non-testing methods are explained 
elsewhere (Worth, 2010). Background information on JRC activities on non-testing methods 
(computational toxicology) can be found on the JRC-IHCP website (http://ecb.jrc.ec.europa.eu/qsar). 
 
Non-testing methods have been found useful to help to make predictions of human health endpoints, 
including the endpoints covered by the requirements of the Cosmetics Directive. Under certain 
circumstances, the information provided by a non-testing method can be considered sufficient to avoid 
the need for animal testing; in other cases, the information can supplement other available data in 
weight-of-evidence assessments of chemical hazard and risk.   
 
During 2008-2009, JRC activities on non-testing methods have focussed on: a) the development of 
technical guidance documents, and publication of state-of-the-art reviews; b) the development, 
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assessment and dissemination of software tools; c) developing and promoting Integrated Testing 
Strategies (ITS). 
 
Since 2009, ECVAM’s innovation pillar also includes these activities of the JRC and will in particular 
focus on integrating its in vitro, non-testing and omics activities with modelling and statistical 
approaches for ITS development and, eventually, their validation.   
 
3.1 DEVELOPMENT OF GUIDANCE ON THE USE OF NON-TESTING METHODS 
 
Guidance on the regulatory use of (Q)SARs and grouping approaches (use of chemical categories and 
read-across), developed mainly for the purposes of REACH, is given in ECHA (2008). The drafting of 
this guidance was led by the JRC, and eventually adopted by the competent authorities, the 
Commission and ECHA. As background to this guidance, a series of case studies has also been 
published (Worth & Patlewicz, 2007). More specific guidance on the use of non-testing methods in 
ecotoxicity assessment (setting of environmental quality standards) has also been published (Crane et 
al, 2008).  
 
According to the REACH guidance (ECHA, 2008), it is possible to use data from (Q)SAR models 
instead of experimental data if each of four main conditions is fulfilled: i) the model used is shown to 
be scientifically valid; ii) the model used is applicable to the chemical of interest; iii) the prediction 
(result) is relevant for the regulatory purpose; and iv) appropriate documentation on the method and 
result is given. 
 
To help the registrants of chemicals provide appropriate documentation on (Q)SARs, several QSAR 
Reporting Formats have been developed by the JRC in consultation with experts nominated by 
Member State authorities and the OECD. This includes a format to document the characteristics and 
validation on the model, the QSAR Model Reporting Format (QMRF), and a format to document the 
generation and interpretation of the prediction, the QSAR Prediction Reporting Format (QPRF). To 
evaluate the reliability of an individual prediction, important aspects of QPRF are transparency in the 
documentation of the training set, the chemical space it represents, and the location of chemical of 
interest within that space. Guidance on how to demonstrate the validity of a (Q)SAR model is provided 
in the ECHA (2008). Further guidance on how to document models in the form of QMRFs and their 
predictions in the form of QPRFs is given on the JRC website (http://ecb.jrc.ec.europa.eu/qsar/qsar-
tools). 
 
The two main approaches for grouping chemicals are the “analogue approach” and the “category 
approach”. The “analogue approach” is used when the grouping is based on a very limited number of 
chemicals, where trends in properties are not apparent. As the number of chemicals being grouped 
increases, the potential for developing hypotheses and making generalisations about the trends also 
increases. The “category approach” is used when the grouping is based on a more extensive range of 
analogues and more endpoints, such that trends across properties can be detected. The term read-across 
is used to describe a method for filling data gaps in either the analogue or category approaches.  
 
Grouping approaches have been applied to industrial chemicals, but in comparison, these approaches 
have been less widely used in the regulatory assessment of cosmetic ingredients. It is therefore 
concluded that read-across could be used more extensively to support the hazard assessment of 
cosmetic ingredients. 
 
In addition to guidance documentation, the JRC has also written reviews on the state-of-the-art of 
existing models for various endpoints, including the following human health effects which are relevant 
to the assessment of cosmetics: a) skin and eye irritation/corrosion (Gallegos Saliner et al., 2008); b) 
skin sensitisation (Alenius et al., 2008; Patlewicz & Worth, 2008; Patlewicz et al., 2008a, 2008b; 
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Roberts & Patlewicz, 2009); c) mutagenicity and carcinogenicity (Benigni et al., 2008a, 2008b); d) 
mammalian toxicity (Tsakovska et al., 2008); and e) reproductive toxicity (Cronin & Worth, 2008). 
 
3.2 IMPLEMENTATION OF NON-TESTING METHODS VIA PUBLICLY ACCESSIBLE 
SOFTWARE 
 
To promote the acceptance of non-testing methods, the JRC has been developing and making freely 
available user-friendly software that provides a means of applying grouping approaches as well as 
(Q)SARs for various endpoints. An overview of these software tools is given in Pavan & Worth 
(2008). These software tools are accessible via the JRC website (http://ecb.jrc.ec.europa.eu/qsar/qsar-
tools). 
 
The Toxtree software implements (Q)SAR models and decision tree approaches for hazard estimation 
and mode-of-action evaluation. The current version (July 2009) implements: a) the Cramer rules for 
applying the Threshold of Toxicological Concern (TTC) concept (Patlewicz et al., 2008c) and an 
extended Cramer scheme; b) the Verhaar rules for aquatic modes of action; and c) the BfR rules for 
predicting the presence and absence of skin irritation and corrosion potential (Gallegos Saliner et al., 
2007); d) the BfR rules for predicting the presence and absence of eye irritation and corrosion potential 
(Tsakovska et al., 2007); e) the Benigni-Bossa rulebase for predicting mutagenicity and 
carcinogenicity (Benigni et al., 2008a); and f) the ToxMic rulebase, which makes predictions of 
mutagenicity and carcinogenicity based on in vivo micronucleus assay data. 
 
To provide a tool for comparing and grouping chemicals, the Toxmatch software has been developed 
(Gallegos Saliner et al., 2008a; Patlewicz et al., 2008d). Toxmatch applies methods of chemical 
similarity analysis to support the formation of chemical categories as well as the application of read-
across. The use of Toxmatch to apply read-across in the assessment of developmental toxicity has been 
demonstrated by Enoch et al. (2009). 
 
The Decision Analysis by Ranking Techniques (DART) tool encodes a number of partial order and 
total order methods for the ranking of chemicals (Pavan & Todeschini, 2008a, 2008b, 2008c). These 
methods can be used to group and sort chemicals according to their relative levels of concern, or to 
group chemicals according to different toxicological profiles. The ranking can be based on molecular 
descriptors and/or experimental (including in vitro) properties. The methods can be used not only to 
prioritise chemicals for further testing, but also to group chemicals (Pavan & Worth, 2008a). 
 
To provide a reliable resource of QMRFs, the JRC is also developing a QSAR Model Database 
(QMDB) which is an inventory of robust summaries of (Q)SARs that can be searched, for example, by 
endpoint or by chemical (sub)structure. This database is accessible at: http://qsardb.jrc.it/qmrf/ 
  
3.3 DEVELOPMENT AND PROMOTION OF INTEGRATED TESTING STRATEGIES 
 
The concepts of integrated testing are explained in a number of papers (e.g. van Leeuwen et al., 2007). 
The JRC has carried out detailed reviews of the state-of-the-art in Integrated Testing Strategies (ITS) 
for various endpoints, including skin and eye irritation/corrosion (Gallegos Saliner & Worth, 2007) 
and skin sensitisation (Patlewicz & Worth, 2008). 
 
In the REACH guidance on chemical safety assessment (ECHA, 2008), ITS have been developed for 
all REACH endpoints. Since these strategies are generally described at a general level, considerable 
research is still needed to develop endpoint-specific strategies in more detail, and to assess their 
impacts, including their benefits (e.g. reduced animal testing) and potential costs (e.g. consequence of 
incorrect predictions). Some of this work is being carried out within the framework of the OSIRIS 
Integrated Project (http://www.osiris-reach.eu), in which the JRC-IHCP is a partner. 
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As an illustration of research needed to further develop endpoint-specific ITS, the JRC has developed 
ITS for skin irritation, as a means of exploring the applicability of novel concepts in the design and 
evaluation of ITS. The work is further described in Hoffmann et al. (2008).  
 
The use of non-testing methods within ITS implies the need for computational tools and a structured 
workflow to facilitate their application. A generic workflow for the implementation of non-testing 
methods has been developed (Bassan & Worth, 2008). 
 
A major outstanding issue is the practical question of how to validate ITS. Some preliminary ideas 
have been developed by ECVAM in collaboration with the EPAA (Kinsner-Ovaskainen et al, 2009a), 
but this is a question which will be further considered and discussed. A second ECVAM-EPAA 
workshop on ITS took place on 12-13 October 2009, with the aims to: 1) discuss to which extent the 
existing validation principles are applicable to the validation of testing strategies (based on selected 
case studies); and 2) develop a draft approach for validation of ITS and apply it to the selected case 
studies. A paper is currently in preparation. 
 
Based on the discussion held, the participants agreed that there is an obvious difference between the 
ITS seen as information gathering process, and testing strategies consisting of alternative methods, 
combined in a predefined way and designed as a replacement of an existing animal test. It was 
generally agreed that only the latter should be formally validated. Also, distinction has to be made 
between the validation of single methods that are used as building blocks of a testing strategy and the 
validation of a testing strategy as a whole.  
 
3.3.1 Validation of building blocks 
 
When assessing the single building block of a testing strategy the following need to be considered:  
a. The test needs to be reliable and, at least, biologically relevant. 
b. The reliable building block will be integrated via a testing strategy. 
c. In some cases, the assessment of predictive capacity of the single building block may 
not be necessary, as long as the predictive capacity of the whole testing strategy is 
demonstrated.  
 
The evaluation of an individual test method to qualify it as a building block would involve at least the 
first 4 modules of validation: Test definition; within-laboratory reproducibility; transferability; 
between-laboratory reproducibility. 
  
In addition: 
d. The biological relevance of the parameter of interest would need to be established. 
e. The chemical selection fits the biological relevance. 
f. The ability to measure the parameter of interest (not the human health effect) would 
have to be assessed. 
 
Test method developers should be encouraged to develop and submit to ECVAM not only tests 
designed as a full replacement of an animal method, but also tests which could be used as part of a 
testing strategy (building blocks). 
 
3.3.2 Validation of ITS as a whole 
 
With regard to the validation of a testing strategy it was concluded that: 
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An Integrated Testing Strategy seen as information gathering process (understood also as a weight-of-
evidence approach) cannot be validated. 
A testing strategy consisting of test methods that are combined in a predefined way and designed for 
replacement of an animal test used for regulatory purposes can be validated, but a detailed list of 
principles to be applied in the construction and assessment of testing strategies should be developed. 
 
In order to successfully validate a testing strategy:  
a. Industry needs to share information on how a given testing strategy is foreseen to be used 
in safety assessment,  
b. ECVAM needs to share with industry and regulators the plans for validation of the 
testing strategy.  
c. Regulators should be involved in these discussions.  
 
4. INTERNATIONAL COLLABORATIONS 
 
ECVAM continues to work closely with its main international partners, such as ICCVAM (USA) and 
JaCVAM (Japan). Relationships with Health Canada were strengthened in the framework of the 
International Cooperation on Alternative Test Methods (ICATM). 
In April 2009 representatives from the validation bodies signed a Memorandum of Cooperation 
promoting enhanced international cooperation and coordination on the scientific validation of non- and 
reduced-animal toxicity testing methods. 
ECVAM liaisons are regularly participating in the different ICCVAM working groups and ICCVAM 
liaisons are attending the validation management group meetings of ECVAM-coordinated validation 
studies. The more recent validation studies are usually led by one of the validation bodies, and set up 
in a way to share, and not duplicate, the work amongst all participating validation bodies. 
  
ECVAM is also closely working with the OECD by either taking the lead for the drafting of new or 
revised OECD Test Guidelines, by participating in OECD expert groups or by coordinating OECD 
validation studies.  ECVAM staff is also regularly sent on secondment to the OECD.  
Finally, ECVAM representatives are actively supporting the various platforms of the European 
Partnership on Alternative Approaches to Animal Testing (EPAA).  
 
5. CONCLUSIONS  
 
The political and regulatory environment considerably changed over the last seven years in relation to 
the development, validation and legal acceptance of alternative methods. Beside being an ethical 
desire, the need for alternative methods has also become a legal necessity, as stipulated in the 7th 
Amendment of the Cosmetics Directive and REACH. 
 
Most of the endpoints falling under the 2009 deadline are covered with validated alternative methods. 
Those human health effects which are not yet completely covered in the sense of a complete 
replacement of the animal test(s) are acute toxicity, eye irritation and genotoxicity.  
 
Within the integrated project A-Cute-Tox, several promising in vitro methods were evaluated and 
combined in in-vitro testing strategies in view to completely replace in vivo testing for acute toxicity 
testing of chemicals. The strategies are currently under evaluation and the final results will become 
available in June 2010. The initial results of the ECVAM validation study on the NRU cytotoxicity test 
to identify non-toxic substances, which are most relevant for use in cosmetics, showed that the test 
method has a high negative predictive value of 90%, but also a high rate of false positives (65%). 
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For genotoxicity and mutagenicity, in vitro methods are in legislation. However, in the current test 
strategy for genotoxicity, positive results obtained from these methods need confirmation by animal 
testing. The negative results on the other hand, are used to classify the substance as not genotoxic. In 
this field, the ECVAM activities are based on the improvement of the test strategy in order to reduce 
the number of false positives resulting from in vitro tests and thus to avoid subsequent animal testing. 
If animal experiments can no longer be carried out from 2009 onwards to confirm the positive in vitro 
results, an economical problem emerges for industry, as too many active cosmetic ingredients will be 
discarded without need. Several approaches, which are currently followed, look promising for making 
solutions available within 2010-2011. 
 
In the field of eye irritation, the evaluation of the individual tests by retrospective and prospective 
validation studies will allow determining the most suitable strategies that utilise the strengths of 
specific in vitro assays for the classification of test chemicals according to their irritation potential. The 
bottom-up or top-down approaches described above identify chemicals not classified as irritant as well 
as ocular corrosives/severe eye irritants, respectively. A default mild/moderate irritant classification 
(GHS Cat. 2 or EU R36) may be acceptable for the remaining chemicals, if the overall accuracy of a 
test method is still relatively high at each tier of the approaches (i.e. generating not too many false 
postives in the first tier of a bottom-up approach and not too many false negatives in the first tier of a 
top-down approach), or if most of the chemicals that are not classified as irritant or are ocular 
corrosives/severe eye irritants are correctly identified using a combination of multiple tests in each tier. 
Otherwise the development and validation of in vitro methods capable of detecting mild/moderate 
irritants (GHS Cat. 2 or EU R36) will be necessary, for inclusion as a last tier in both the top-down and 
bottom-up approaches. 
 
For the complex endpoints, several research initiatives were launched over the last 5 years to make 
new approaches available for validation. 
These projects included the development and optimisation of alternative methods in the fields of 
reproductive toxicology (Re-Pro-Tect; 2004-2009), acute toxicity (A-cute-Tox; 2004-2009), skin and 
respiratory sensitisation (Sens-it-iv; 2005-2010), carcinogenicity (Carcinogenomics; 2006-2011) and 
chronic toxicity (Predict-i.v.; 2008-2013) and more recently the COLIPA-DG RTD Joint Research 
Inititiative, which resulted into a new FP7 call in 2009, focusing on repeated dose toxicity.  
 
Those research projects which will soon come to an end will deliver some promising in vitro methods 
which may enter the ECVAM validation process in the near future and new approaches to combine the 
different tests in the most optimal way are needed for these endpoints. Although a considerable 
reduction in the number of animals used has already been achieved by using alternative methods, full 
replacement of the animal test(s) by 2013 remains of a problem, despite the huge amount of work and 
efforts which are currently invested in many different aspects of research, development, optimisation 
and validation of alternative methods and testing strategies.  
A more positive attitude towards the acceptance of stringently-validated alternative methods at the 
regulatory level would also be most beneficial.  
 
Finally, the substitution of animal safety tests with highly modern animal-free technology which 
ensures the same level of protection of the population, should remain a common international goal, 
driven by strong ethical considerations. 
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ACRONYMS 
 
A.704 Human, kidney, adenocarcinoma 
AR-CALUX® Human osteoblastic osteosarcoma U2 OS cell line transfected with the human 
androgen receptor 
BALB/c 3T3  Mouse Embryonic Fibroblasts  
BBB   Blood-Brain Barrier 
BCOP   Bovine Corneal Opacity and Permeability  
Caco-2   Human colonic adenocarcinoma cell line 
CFU-GM  Colony Forming Unit-Granulocyte Macrophage 
CM   Cytosensor Microphysiometer 
COLIPA European Cosmetic, Toiletry and Perfumery Association 
CRO   Contract Research Organisation 
CsA                             Cyclosporine A 
CTA   Cell Transformation Assay 
CYP   Cytochrome P450 
DART   Decision Analysis by Ranking Techniques 
DNA   Deoxyribonucleic Acid 
DPRA   Direct Peptide Reactivity Assay 
EC   European Commission 
ECB   European Chemical Bureau 
ECHA   European Chemicals Agency 
ECVAM  European Centre for the Validation of Alternative Methods 
EMT   Epithelial Mesenchymal Transition 
EPA   Environmental Protection Agency 
EPAA   European Partnership on Alternative Approaches to animal testing 
ER-CALUX® Human breast cancer cell line T47D cells, expressing endogenous estrogen 
receptors 
ESAC ECVAM Scientific Advisory Committee 
EST Embryonic Stem cell Test 
EU European Union 
FL Fluorescein Leakage 
GFAP Glial fibrillar acidic protein 
GHS   Globally Harmonised Classification System 
GJIC   Gap Junction Intercellular Communication 
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HCE   Human Corneal Epithelium 
h-CLAT  human Cell Line Activation Test 
HepaRG  Human hepatoma cells 
HepG2 cell/protein Human liver cell line (hepatocellular cacinoma) 
hESC   Human Embryonic Stem Cells 
HET-CAM  Hen’s Egg Test on the Chorioallantoic Membrane 
HIA   Human intestinal absorption 
HK-2   Human Kidney-2 cell line 
HSP32   Heat shock protein 32 
ICCVAM Interagency Coordinating Committee on the Validation of Alternative Methods 
ICE   Isolated Chicken Eye  
IFN-γ   Interferon- Gamma 
IL-1   Interleukin-1 
IL-6   Interleukin-6 
IRE   Isolated Rabbit Eye 
ITS   Integrated Testing Strategies 
JACVAM  Japanese Centre for the Validation of Alternative Methods 
JRC   Joint Research Centre 
L929                           Mouse fibroblast cell line  
LD50   Lethal Dose killing 50% of the animals 
LDH   Lactate dehydrogenase 
LLNA   Local Lymph Node Assay 
LVET   Low Volume Eye Test 
MELN MCF-7 human breast cancer cells (ERα+) transfected with the estrogen 
responsive gene ERE-ß Glob-Luc-SVNeo 
MBP Myelin basic protein 
MTT   3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
MUSST                       Myeloid U939 Skin Sensitisation Test 
NC3Rs  National Centre for the 3Rs (replacement, refinement, reduction) 
NF-H   Neurofilament- high 
NHEK   Normal Human Epidermal Keratinocytes 
NICEATM The National Toxicology Program Interagency Center for the Evaluation of 
Alternative Toxicological Methods 
Nrf2 Nuclear factor-erythroid 2 
NRR Neutral Red Release 
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NRU   Neutral Red Uptake 
NRU PT  Neutral Red Uptake Phototoxicity Test  
OECD                         Organisation for Economic Cooperation and Development  
PALM   Human prostate adenocarcinoma cell line Androgen Luciferase     
                                    MMTV 
PBMC                         human Peripheral Blood Mononuclear Cells 
PLS   Partial Least Square analysis 
PS                                Performance Standards 
QMDB  QSAR Model Database 
QMRF   QSAR Model Reporting Format 
QPRF   QSAR Prediction Reporting Format 
(Q)SAR  (Quantitative) Structure-Activity Relationship 
RBC   Red Blood Cell  
REACH  Registration, Evaluation, Authorisation and restriction of Chemicals 
RhE   Reconstructed Human Epidermis 
RhT   Reconstructed Human Tissue 
ROS   Reactive Oxygen Species 
SerW3   Sertoli cell line 
SHE   Syrian Hamster Embryonic cell line  
SHSY5Y  Human neuroblastoma cells 
SMEs   Small and Medium-sized Enterprises 
SOP   Standard Operating Procedure 
STREP  Specific Targeted Research Project 
TNF-α   Tumor Necrosis Factor alpha 
TG   Test Guideline 
TTC   Treshold of Toxicological Concern 
WEC   Whole Embryo Culture 
 43
REFERENCES  
 
Alenius, H., Roberts, D.W., Tokura, Y., Lauerma, A., Patlewicz, G. & Roberts, M.S. (2008). Skin, Drug and 
Chemical Reactions. Drug Discovery Today: Disease Mechanisms 5, 211-220 
Bacqueville, D. & Mavon, A. (2009). Comparative analysis of solar radiation-induced cellular damage between 
ex vivo porcine skin organ culture and in vitro reconstituted human epidermis. International Journal of 
Cosmetic Science. 31, 293-302. 
Balls, M., Amcoff, P., Bremer, S., Casati, S., Coecke S., Clothier, R., Combes, R., Corvi, R., Curren, R., Eskes, 
C., Fentem, J., Gribaldo, L., Halder, M., Hartung, T., Hoffmann, S., Schechtman, L., Scott L., Spielmann, H., 
Stokes, W., Tice, R., Wagner D. &  Zuang V. (2006). The principles of weight of evidence validation of test 
methods and testing strategies. ATLA 34, 1-19. 
Barai, N.D., Boyce, S.T., Hoath, S.B., Visscher, M.O. & Kasting, G.B. (2008). Improved barrier function 
observed in cultured skin substitutes developed under anchored conditions. Skin Research and Technology 14, 
418-424. 
Basketter, D., Cockshott, A., Corsini, E., Gerberick, G.F., Idehara, K., Kimber, I., Van Loveren, H., Matheson, 
j., Mehling, A., Omori, T., Rovida, C., Sozu., Takeyoshi, M. & Casati S. (2008). An Evaluation of Performance 
Standards and Non-radioactive Endpoints for the Local Lymph Node Assay. The Report and Recommendations 
of ECVAM Workshop 65a.  ATLA 36, 243-257.  
Bassan, A. & Worth, A.P. (2008). The Integrated Use of Models for the Properties and Effects of Chemicals by 
means of a Structured Workflow. QSAR & Combinatorial Science 27, 6-20.  
Benigni, R., Bossa, C., Jeliazkova, N., Netzeva, T. & Worth, A. (2008a). The Benigni / Bossa rulebase for 
mutagenicity and carcinogenicity – a module of Toxtree. European Commission report EUR 23241 EN. 
European Commission-Joint Research Centre, Ispra, Italy. Available  from: 
http://ecb.jrc.ec.europa.eu/qsar/publications. Accessed on 20.12.2009. 
Benigni, R., Worth, A., Netzeva, T., Jeliazkova, N., Bossa, C., Gruska, A. & Franke, R. (2008b). Structural 
Motifs Modulating the Carcinogenic Risk of Aromatic Amines. Environmental and Molecular Mutagenesis 50, 
152-161.  
Borlon, C., Godard, P., Eskes, C., Hartung T., Zuang, V. & Toussaint, O. (2007). The usefulness of 
toxicogenomics for predicting acute skin irritation on in vitro reconstructed human epidermis. Toxicology 
241(3), 157-166. 
Bouvier d’Yvoire, M., Prieto, P., Blaauboer, B.J., Bois, F.Y., Boobis, A., Brochot, C., Coecke, S., Freidig, A., 
Gundert-Remy, U., Hartung, T., Jacobs, M.N., Lavé, T., Leahy, D.E., Lennernäs, H., Loizou, G.D., Meek, B., 
Pease, C., Rowland, M., Spendiff, M., Yang, J. & Zeilmaker, M. (2007). Physiologically-based Kinetic 
Modelling (PBK Modelling): Meeting the 3Rs Agenda. The Report and Recommendations of ECVAM 
Workshop 63. ATLA 35, 661-671. 
Bremer, S., Cortvrindt, R., Daston, G., Eletti, B., Mantovani, A., Maranghi, F., Pelkonen, O.,  Ruhdel, I. & 
Spielmann, H. (2005).Subchapter 3.11. Reproductive and developmental toxicity. In Alternative (non-animal) 
Methods for Cosmetics Testing: Current Status and Future Prospects (Eskes C., Zuang V. eds). ATLA 33, Suppl. 
1, 183-209. 
Bulgheroni, A., Kinsner-Ovaskainen, A., Hoffmann, S., Hartung, T. & Prieto, P. (2009). Estimation of acute 
oral toxicity using the No Adverse Effect Level (NOAEL) from the 28-day repeated dose toxicity studies in rats. 
Regulatory Toxicology and Pharmacology 53 (1), 16-19. 
 
Coecke, S., Rogiers, V., Bayliss, M., Castell, J., Doehmer, J., Fabre, G., Fry, J., Kern, A. & Westmoreland, C. 
(1999). The use of long-term hepatocytes cultures for detecting induction of drug metabolising enzymes: the 
 44
current status. ECVAM hepatocytes and metabolically competent systems Task Force Report 1. ATLA 27, 579-
638. 
Coecke, S., Blaauboer, B.J., Elaut, G., Freeman, S., Freidig, A., Gensmantel, N., Hoet, P., Kapoulas, V.M., 
Ladstetter, B., Langley, G., Leahy, D., Mannens, G., Meneguz, A., Monshouwer, M., Nemery, B., Pelkonen, O., 
Pfaller, W., Prieto, P., Proctor, N., Rogiers, V., Rostamin-Hodjegan, A., Sabbioni, E., Steiling, W. & van de 
Sandt, J.J.M. (2005). Toxicokinetics and Metabolism. In Alternative (non-animal) Methods for Cosmetics 
Testing: Current Status and Future Prospects (Eskes C., Zuang V. eds). ATLA 33, Suppl. 1, 147-175. 
Coecke, S., Ahr, H., Blaauboer, B.J., Bremer, S., Casati, S., Castell, J., Combes, R., Corvi, R., Crespi, 
C.L., Cunningham, M.L., Elaut, G., Eletti, B., Freidig, A., Gennari, A., Ghersi-Egea, J.F., Guillouzo, 
A., Hartung, T., Hoet, P., Ingelman-Sundberg, M., Munn, S., Janssens, W., Ladstetter, B., Leahy, D., 
Long, A., Meneguz, A., Monshouwer, M., Morath, S., Nagelkerke, F., Pelkonen, O., Ponti, J., Prieto, P., 
Richert, L., Sabbioni, E., Schaack, B., Steiling, W., Testai, E., Vericat, J.A. & Worth, A. (2006). 
Metabolism: A Bottleneck in In Vitro Toxicological Test Development. The Report and Recommendations of 
ECVAM Workshop 54.  ATLA 34, 1–36. 
Combes, R., Balls, M., Curren, R., Fischbach, M., Fusenig, N., Kirkland, D, Lasne, A., Landolph, J., LeBoeuf, 
R., Marquardt, H., McCormick, J., Mueller, L., Rivedal, E., Sabbioni, E.,Tanaka, N., Vasseur, P. & Yamasaki, 
H. (1999). Cell transformation assay as predictors of hyman carcinogenicity. ATLA 27, 745-767.    
Cooper, R.L., Lamb, J.C., Barlow, S.M., Bentley, K., Brady, A.M., Doerrer, N.G., Eisenbrandt, D.L., Fenner-
Crisp, P.A., Hines, R.N., Irvine, L.F., Kimmel, C.A., Koeter, H., Li, A.A., Makris, S.L., Sheets, L.P., Speijers, 
G. & Whitby K. (2006). A tiered approach to life stages testing for agricultural chemical safety 
assessment. Crit Rev Toxicol. 36 (1):69-98.  
Crane, M., Watts, C., Daginnus, K. & Worth, A. (2008). Possible Application of Non-Testing Methods in 
Setting Environmental Quality Standards (EQS). European Commission report EUR 23758 EN. European 
Commission-Joint Research Centre, Ispra, Italy. Available from: http://ecb.jrc.ec.europa.eu/qsar/publications/. 
Accessed on 20.12.2009 
Creton, S., Dewhurst, I.C., Earl, L.K., Gehen, S.C., Guest, R.L., Hotchkiss, J.A., Indans, I., Wollhiser, M.R. & 
Billington, R. (2010) Acute toxicity testing of chemicals-Opportunities to avoid redundant testing and use of 
alternative approaches. Critical Reviews in Toxicology 40, 50-83.  
Cronin, M.T.D. & Worth, A.P. (2008). (Q)SARs for Predicting Effects Relating to Reproductive Toxicity. 
QSAR & Combinatorial Science 27, 91-100.  
Culot, M., Lundquist, S., Vanuxeem, D., Nion, S., Landry, C., Delplace, Y., Dehouck, M.P., Berezowski, V., 
Fenart, L. & Cecchelli R. (2008) An in vitro blood-brain barrier model for high throughput (HTS) toxicological 
screening. Toxicol in Vitro 22(3):799-811.  
EC (2000) Commission Directive 2000/33/EC of 25 April 2000 adapting to technical progress for the 27th time 
Council Directive 67/548/EC on the approximation of laws, regulations and administrative provisions relating to 
the classification, packaging and labelling of dangerous substances. Annex V B.41 Phototoxicity - in vitro 3T3 
NRU phototoxicity test. Official Journal of the European Communities L136, 98-107. 
EC (2008) Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 
on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 
67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006. Official Journal of the European 
Union L353, 1-1355. 
EC (2009). Annex III. Method B.46. In vitro Skin Irritation: Reconstructed Human Epidermis Model Test. pp. 
24-35. In: Commission Regulation (EC) No 761/2009 of 23 July 2009 amending for the purpose of its 
adaptation to technical progress, Regulation No. 440/2008 laying down test methods pursuant to Regulation 
(EC) No. 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH). Official Journal of the European Union L220, 1-94.  
 45
ECHA (2008).Guidance on Information Requirements and Chemical Safety Assessment. European Chemicals 
Agency, Helsinki, Finland. Available at: 
http://reach.jrc.it/docs/guidance_document/information_requirements_en.htm. Accessed on 15.12.2009 
 
Enoch, S.J., Cronin, M.T.D, Madden, J.C. & Hewitt, M (2009). Formation of structural categories to allow for 
read-across for teratogenicity." QSAR & Combinatorial Science 28, 696-708. 
ESAC (2007a) Statement on the validity of in vitro tests for skin irritation. Available at: 
http://ecvam.jrc.ec.europa.eu/ under “Publications”, “ESAC statements”, accessed on 29.11.2009. 
ESAC (2007b) ESAC Statement on the conclusions of the ICCVAM retrospective study on Organotypic in vitro 
assays as screening tests to identify potential ocular corrosives and severe irritants as determined by US EPA, 
EU (R41) AND UN GHS classifications in a tiered testing strategy, as part of a weight of evidence approach. 
Available at: http://ecvam.jrc.ec.europa.eu/ under “Publications”, “ESAC statements”, accessed on 29.11.2009. 
ESAC (2007c) Statement on the Scientific Validity of the reduced-Local Lymph Node Assay. Available at 
http://ecvam.jrc.ec.europa.eu/ under "Publications", "ESAC statements". Accessed on 29.11.2009. 
ESAC (2008a) Statement on the Scientific Validity of In vitro tests for Skin Irritation testing (SkinEthic and 
modified EpiDerm). Available at: http://ecvam.jrc.ec.europa.eu/ under "Publications", "ESAC statements". 
Accessed on 18.12.2009. 
 
ESAC, (2008b) ESAC Statement on the Performance Standards (PSs) for the Local Lymph Node Assay 
(LLNA). Available at: http://ecvam.jrc.ec.europa.eu/ under “Publications”, “ESAC statements”, accessed on 
29.11.2009. 
 
ESAC (2009a) Updated Statement on the Performance under UN GHS of three in vitro assays for Skin Irritation 
testing and the Adaptation of the Reference chemicals and defined accuracy values of the ECVAM Skin 
Irritation Performance Standards. Available at: http://ecvam.jrc.ec.europa.eu/ under "Publications", "ESAC 
statements". Accessed on 16.12.2009. 
 
ESAC (2009b) ESAC Statement on the scientific validity of an in vitro test method for skin corrosivity testing. 
Available at: http://ecvam.jrc.ec.europa.eu under "Publications", "ESAC statements". Accessed on 16.12.2009. 
 
ESAC (2009c) ESAC statement on the scientific validity of two in vitro eye irritation test methods. Available at: 
http://ecvam.jrc.ec.europa.eu under "Publications", "ESAC statements". Accessed on 16.12.2009. 
 
ESAC (2009d) ESAC statement on the use of existing LVET data for classification and labelling purposes. 
Available at: http://ecvam.jrc.ec.europa.eu under "Publications", "ESAC statements". Accessed on 16.12.2009. 
 
Eskes, C., Cole, T., Hoffmann, S., Worth, A., Cockshott, A., Gerner, I. & Zuang.V (2007). ECVAM 
International Validation Study on In Vitro Tests for Acute Skin Irritation: Selection of Test Chemicals. ATLA 
35, 603-619. 
EU (2003) Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003 amending 
Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic 
products. Official Journal of the European Union L66, 11.03.2004. 
Freeman, S., Alépée, N., Barroso, J., Cole, T., Compagnoni, A., Rubingh, C., Eskes, C., Lammers, J., 
McNamee, P., Pfannenbecker, U. & Zuang, V. (2010). Prospective Validation Study of Reconstructed Human 
Tissue Models for Eye Irritation Testing. Proceedings of the 7th World Congress on Alternatives and Animal 
Use in the Life Sciences. Rome, Italy. ALTEX. In press. 
Gallegos Saliner, A., Tsakovska, I., Pavan, M., Patlewicz, G. & Worth, A.P. (2007). Evaluation of SARs for the 
prediction of skin irritation/corrosion potential. Structural inclusion rules in the BfR decision support system. 
SAR & QSAR in Environmental Research 18, 331-342.  
 46
Gallegos Saliner, A. & Worth, A.P. (2007). Testing Strategies for the Prediction of Skin and Eye Irritation and 
Corrosion for Regulatory Purposes. European Commission report EUR 22881 EN. European Commission-Joint 
Research Centre, Ispra, Italy. Available from: http://ecb.jrc.ec.europa.eu/qsar/publications/. Accessed on 
12.01.2010. 
Gallegos Saliner, A., Patlewicz, G. & Worth, A.P. (2008). A Review of (Q)SAR Models for Skin and Eye 
Irritation and Corrosion. QSAR & Combinatorial Science 27, 49-59.  
Gallegos Saliner, A., Poater, A., Jeliazkova, N., Patlewicz, G. & Worth, A.P. (2008a). Toxmatch - A Chemical 
Classification and Activity Prediction Tool based on Similarity Measures. Regulatory Toxicology and 
Pharmacology 52, 77-84.  
Gomez-Lechon, M.J, Donato, M.T., Martinez-Romero, A., Jimenez, N., Castell, J.V. & O’Connor, E. (2007). A 
human hepatocellular in vitro model to investigate steatosis. Chemico-Biological Interactions 165, 106–116. 
Gregoire, S., Ribaud, C., Benech, J.R., Meunier, A., Garrigues-Mazert, A & Guy, R.H. (2009) Prediction of 
chemical absorption into and through the skin from cosmetic and dermatological formulations. British Journal 
of Dermatology, 160, 80-91. 
Griesinger, C., Barroso, J., Zuang, V., Cole, T., Genschow, E. & Liebsch, M. (2010). Explanatory Background 
Document to the OECD Draft Test Guideline on in vitro Skin Irritation Testing. Available at: 
http://ecvam.jrc.ec.europa.eu/  under “Validation Study Documents”. 
 
Halle, W. (2003). The registry of cytotoxicity: toxicity testing in cell cultures to predict acute toxicity (LD50) 
and to reduce testing in animals. ATLA 31, 89-198. 
Hallier-Vanuxeem, D., Prieto, P., Culot, M., Diallo, H., Landry, C., Tähti, H. & Cecchelli, R. (2009). New 
strategy for alerting central nervous system toxicity: Integration of blood–brain barrier toxicity and permeability 
in neurotoxicity assessment. Toxicology in Vitro 23, 447-453.  
Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder, M., Hoffmann, S., 
Roi, A.J., Prieto, P., Sabbioni, E., Scott, L., Worth, A. & Zuang, V. (2004). A Modular Approach to the 
ECVAM Principles on Test Validity. ATLA 32, 467-472. 
Hoffmann, S., Gallegos Saliner, A., Patlewicz, G., Eskes, C., Zuang, V. & Worth, A.P. (2008). A feasibility 
study developing an integrated testing strategy assessing skin irritation potential of chemicals. Toxicology 
Letters 180, 9-20.  
ICCVAM-NICEATM (2002). Current status of test methods for detecting endocrine disrupters in vitro estrogen 
receptor transcriptional activation assays. Available at: 
http://iccvam.niehs.nih.gov/methods/endocrine/end_bckgnd.htm. Accessed on 20.12.2009. 
Jacobs, M.N, Janssens, W., Bernauer, U, Brandon, E., Coecke, S., Combes, R., Edwards, P., Freidig, A., 
Freyberger, A., Kolanczyk, R., Mc Ardle, C., Mekenyan, O., Schmieder, P., Schrader, T., Takeyoshi, M. & van 
der Burg, B. (2008). The use of metabolising systems for in vitro testing of endocrine disruptors. Curr Drug 
Metab 9, 796-826. 
Jennings, P., Aydin, S., Bennett, J., McBride, R., Weiland, C., Tuite, N., Gruber, L.N., Perco, P., Gaora, P.O., 
Ellinger-Ziegelbauer, H., Ahr, H.J., Kooten, C.V., Daha, M.R., Prieto, P., Ryan, M.P., Pfaller, W. & 
McMorrow, T. (2009). Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome 
alterations due to Cyclosporine A exposure and medium exhaustion. Toxicology in Vitro 23, 486-99.  
Jírová, D., Kejlová, K., Bendová, H., Ditrichová, D. & Mezuláníková, M. (2005). Phototoxicity of bituminous 
tars-correspondence between results of 3T3 NRU PT, 3D skin model and experimental huamn data. Toxicology 
in Vitro 19, 931-934. 
Jones, P.A., King, A.V., Earl, L.K. & Lawrence, R.S. (2003). An assessment of the phototoxic hazard of a 
personal product ingredient using in vitro assays. Toxicology in Vitro 17, 471-80. 
 47
Kandárová, H. (2009). In vitro phototoxicity studies with reconstructed human skin equivalents. Altex, 26: 
Special Issue, 241 
Kejlová, K., Jírová, D., Bendová, H., Kandárová, H., Weidenhoffer, Z., Kolářová, H. & Liebsch, M. (2007). 
Phototoxicity of bergamot oil assessed by in vitro techniques in combination with human patch tests. Toxicology 
in Vitro 21, 1298-1303. 
Kimber, I., Agius, R., Basketter, D.A., Corsini, E., Cullinan, P., Dearman, R.J., Gimenez-Arnau, E., Greenwell, 
L., Hartung, T., Kuper, F., Maestrelli, P., Roggen, E. & Rovida, C. (2007). Chemical respiratory allergy: 
opportunities for hazard identification and characterisation. The report and recommendations of ECVAM 
Workshop 60. ATLA 35, 243–265. 
Kinsner-Ovaskainen, A., Rzepka, R., Rudowski, R., Coecke, S., Cole, T. & Prieto, P. (2009). Acutoxbase, an 
innovative database for in vitro acute toxicity studies. Toxicology in Vitro 23, 476–485. 
Kinsner-Ovaskainen, A., Akkan. Z., Casati, S., Coecke, S., Corvi, R., Dal Negro, G., De Bruijn, J., De Silva, O., 
Gribaldo, L., Griesinger, C., Jaworska, J., Kreysa, J., Maxwell, G., McNamee, P., Price, A., Prieto, P., Schubert, 
R., Tosti, L., Worth, A. & Zuang, V. (2009a). Report from the EPAA-ECVAM Workshop on ‘Overcoming 
Barriers to Validation of Non-Animal Partial Replacement Methods / Integrated Testing Strategies. ATLA 4, 
437-44. 
Kirkland, D., Pfuhler, S., Tweats, D., Aardema, M., Corvi, R., Darroudi, F., Elhajouji, A., Glatt, H., Hastwell, 
P., Hayashi, M., Kasper, P., Kirchner,  Lynch, A., Marzin, D., Maurici, D., Meunier, J.-R., Müller, L., Nohynek, 
g., Parry, J., Parry, E., Thybaud, V., Tice, R., van Benthem, J., Vanparys, P. & White, P. (2007). How to reduce 
false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up 
animal tests: Report of an ECVAM workshop. Mutation Research 628, 31-55. 
Kirkland, D., Kasper, P., Müller, L., Corvi, R. & Speit, G. (2008). Recommended lists of genotoxicic and non-
genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: A follow-up to 
an ECVAM workshop. Mutation Research 653, 99-108.  
Lelièvre, D., Justine, P., Christiaens, F., Bonaventure, N., Coutet, J., Marrot, L. & Cotovió, J. (2007). 
The EpiSkin phototoxicity assay (EPA): development of an in vitro tiered strategy using 17 reference chemicals 
to predict phototoxic potency. Toxicology in Vitro 21, 977-95.  
Liebsch, M., Döring, B., Donelly, T.A., Logemann, P., Rheins, L.A. & Spielmann, H. (1995). Application of the 
human dermal model Skin2 ZK 1350 to phototoxicity and skin corrosivity testing. Toxicology in Vitro 9, 557-
562. 
Liebsch, M., Barrabas, C., Traue, T. & Spielmann, H. (1997). Entwicklung eines in vitro Tests auf dermale 
Phototoxizitaet in einem Modell menschlicher Epidermis (EpiDermTM). ALTEX 14, 165-174. 
Liebsch, M., Spielmann, H., Pape, W., Krul, C., Deguercy, A., & Eskes, C. (2005). UV-induced Effects in 
Alternative (Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects. Eskes, C. and 
Zuang, V. (eds.). ATLA 33 Suppl. 1, 131-146. 
Loizou, G., Spendiff, M., Barton, H., Bessems, J., Bois, F.Y., Bouvier d'Yvoire, M., Buist, H., Clewell III, H., 
Meek, B., Gundert-Remy, U. & Schmitt, W. (2008). Development of Good Modelling Practice for 
Physiologically Based Pharmacokinetic Models for Use in Risk Assessment: The First Steps. Regulatory 
Toxicology and Pharmacology 50, 400-411. 
Loizou, G. (2009). The rapid generation of PBPK models: A tool for good modelling practice. Toxicology 
Letters 189. Abstracts of the 46th Congress of the European Societies of Toxicology S24. 
Lynch, A.M. & Wilcox, P. (2010). Review of the performance of the 3T3 NRU in vitro phototoxicity assay in 
the pharmaceutical industry. Exp Toxicol Pathol, doi: 10.1016 
 48
Marrot, L., Belaidi, J.P., Labarussiat, A., Perez, P., Meunier, J.R. (2009). An in vitro strategy for phototoxicity 
testing based on complementary biological endpoints. Altex, 26: Special Issue, 279. 
Marx-Stoelting, P., Adriaens, E., Ahr, H.J., Bremer, S., Garthoff, B., Gelbke, H.P., Piersma, A., Pellizzer, C., 
Reuter, U., Rogiers, V., Schenk, B., Schwengberg, S., Seiler, A., Spielmann, H., Steemans, M., Stedman, D.B., 
Vanparys, P., Vericat, J.A., Verwei, M., van der Water, F., Weimer, M., & Schwarz, M. (2009). A review of the 
implementation of the embryonic stem cell test (EST). The report and recommendations of an 
ECVAM_ReProTect Workshop. ATLA 37, 313-328. 
Maurici, D., Aardema, M., Corvi, R., Kleber, M., Krul, C., Laurent, C., Loprieno, N., Pasanen, M., Pfuhler, S., 
Phillips, B., Sabbioni, E., Sanner, T. & Vanparys, P. (2005). Genotoxicity and Mutagenicity in Alternative 
(Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects. Eskes, C. and Zuang, V. 
(eds.). ATLA 33 Suppl. 1, 117-130. 
Moore, N., Bremer, S., Carmichael, N., Daston, G., Dent, M., Gaoua-Chapelle, W., Hallmark, N., 
Hartung, T., Holzum, B., Hübel, U., Meisters, M.L., Schneider, S., van Ravenzwaay, B. & Hennes C 
(2009). A modular approach to the extended one-generation reproduction toxicity study. Theoutcome of an 
ECETOC Task Force and International ECETOC/ECVAM Workshop. ATLA 37, 219-225. 
OECD (2004a). OECD Guidelines for the Testing of Chemicals No. 404: Acute Dermal Irritation/Corrosion, 
13pp. Paris, France: Organisation for Economic Cooperation and Development. 
OECD (2004b). OECD Guidelines for the Testing of Chemicals No. 432: In Vitro 3T3 NRU phototoxicity test.  
15pp. Paris, France: Organisation for Economic Co-operation and Development.  
OECD (2004c). OECD Guidelines for the Testing of Chemicals No. 428: Skin absorption: in vitro method, 8pp. 
Paris, France: Organisation for Economic Cooperation and Development. 
OECD (2004d). Guidance Document for the Conduct of Skin Absorption Studies, Environment Directorate. In 
OECD Environmental Health and Safety Publications, Series on Testing and Assessment No. 28. Paris, France: 
Organization for Economic Cooperation and Development. 
OECD (2007). Detailed review on cell transformation assays for detection of chemical carcinogens, OECD 
Environment, Health and Safety Publications, Series on Testing and Assessment, No. 31 (2007). 
Onoue, S., Igarashi, N., Yamada, S., Tsuda, Y. (2008). High-throughput reactive oxygen species (ROS) assay: 
an enabling technology for screening phototoxic potential of pharmaceutical substances. Journal of 
Pharmaceutical and Biomedical Analysis 46, 187-193. 
Pavan, M. & Worth, A. (2008). Publicly-accessible QSAR software tools developed by the Joint Research 
Centre. SAR and QSAR in Environmental Research 19, 785-799.  
Pavan, M. & Todeschini, R. (2008a). Optimization: Multi-criteria Decision Making methods, in Comprehensive 
Chemometrics. B Walczak, RT Ferré & S Brown (Eds), Elsevier, Oxford, UK.  
Pavan, M. & Todeschini, R. (2008b). Total Order Ranking Methods, in Scientific Data Ranking Methods: 
Theory and Applications. 1st Edition. M Pavan & R Todeschini (Eds). Elsevier, Oxford, UK, pp. 51-72.  
Pavan, M. & Todeschini, R. (2008c). Scientific Data Ranking Methods: Theory and Applications. Data 
Handling in Science and Technology Vol. 27. 1st Edition. Elsevier, Oxford, UK, 213 pp.  
Pavan, M. & Worth, A. (2008a). A set of case studies to illustrate the applicability of DART (Decision Analysis 
by Ranking Techniques) in the ranking of chemicals. European Commission report EUR 23481 EN. European 
Commission-Joint Research Centre, Ispra, Italy. Available from: http://ecb.jrc.ec.europa.eu/qsar/publications. 
Accessed on 20.12.2009. 
 49
Patlewicz, G. & Worth, A. (2008). Review of Data Sources, QSARs and Integrated Testing Strategies for Skin 
Sensitisation. European Commission report EUR 23225 EN. European Commission-Joint Research Centre, 
Ispra, Italy. Available from: http://ecb.jrc.ec.europa.eu/qsar/publications. Accessed on 20.12.2009. 
Patlewicz, G., Roberts, D.W. & Uriarte, E. (2008a). A comparison of reactivity schemes for the prediction of 
skin sensitization potential. Chemical Research in Toxicology 21, 521–541.  
Patlewicz, G., Aptula, A.O., Roberts, D.W. & Uriarte, E. (2008b). A Minireview of Available Skin Sensitization 
(Q)SARs/Expert Systems. QSAR & Combinatorial Science 27, 60-76.  
Patlewicz, G., Jeliazkova, N., Safford, R.J., Worth, A.P. & Aleksiev, B. (2008c). An evaluation of the 
implementation of the Cramer classification scheme in the Toxtree software. SAR and QSAR in Environmental 
Research 19, 495-524.  
Patlewicz, G., Jeliazkova, N., Gallegos Saliner, A. & Worth, A.P. (2008d). Toxmatch – A new software tool to 
aid in the development and evaluation of chemically similar groups. SAR and QSAR in Environmental Research 
19, 397-412.  
Pfuhler, S., Kirkland, D., Kasper, P., Hayashi, M., Vanparys, P., Carmichael, P., Dertinger, S., 
Eastmond, D., Elhajouji, A., Krul, C., Rothfuss, A., Schoening, G., Smith ,A., Speit, G., Thomas, C., 
van Benthem, J. & Corvi, R. (2009). Reduction of use of animals in regulatory genotoxicity testing: 
Identification and implementation opportunities-Report from an ECVAM workshop. Mutat Res. 680 (1-2), 31-
42 
Portes, P., Pygmalion, M.J., Popovic, E., Cottin, M. and Mariani, M. (2002). Use of human reconstituted 
epidermis EpiSkin for assessment of weak phototoxic potential of chemical compounds. Photodermatol 
Photoimmunol Photomed. 18, 96-102.  
 
Prieto, P., Hoffmann, S., Tirelli, V., Tancredi, F., Gonzalez, I., Bermejo, M. & De Angelis, I. (2010). 
Prevalidation study of two Caco-2 cell models for oral absorption: report on the within-laboratory, between 
laboratory variability and predictive capacity. Submitted to ATLA. 
Ray, R.S., Agrawal, N., Sharma, A. & Hans, R.K. (2008). Use of L-929 cell line for phototoxicity assessment. 
Toxicology in Vitro 22, 1775-1781. 
Roberts, D.W. & Patlewicz, G. (2009). Chemistry Based Non-Animal Predictive Modeling For Skin 
Sensitization, in Ecotoxicology Modeling, Emerging Topics in Ecotoxicology, Vol. 2. J Devillers (Ed.). 
Springer, Heidelberg, Germany. 
Roggen, E., Aufderheide, M., Cetin, Y., Dearman, R., Gibbs, S., Hermanns, I., Kimber, I., Regal, J.F., Rovida, 
C., Warheit, D.B., Uhlig, S. & Casati, S. (2008). The Development of Novel Approaches to the Identification of 
Chemical and Protein Respiratory Allergens. ATLA 36, 591-598. 
Rohacova, J., Marin, M.L., Martínez-Romero, A., O’Connor, J.E., Gomez-Lechon, M.J., Donato, M.T., Castell, 
J.V. & Miranda, M.A. (2008). Photophysical characterization and flow cytometry applications of 
cholylamidofluorescein, a fluorescent bile acid scaffold. Photochem Photobiol Sci. 7, 860-866. 
 Rohacova, J., Marín, M.L., Martinez-Romero, A., Diaz, L., O’Connor, J.E., Gomez-Lechon, M.J., Donato, 
M.T., Castell, J.V. & Miranda MA. (2009). Fluorescent Benzofurazan-Cholic Acid Conjugates for in vitro 
Assessment of Bile Acid Uptake and Its Modulation by Drugs. ChemMedChem. 4, 466-472. 
Ryu, Y., Jung, H. & Lee, S. (2009). Alternative in vitro phototoxicity test using reconstructed skin model 
KeraSkin™. Altex 26: Special Issue, 307 
Schäfer-Korting, M., Bock, U., Gamer, A., Haberland, A., Haltner-Ukomadu, E., Kaca, M., Kamp, H., 
Kietzmann, M., Korting, H-C., Krächter, H-U., Lehr, C-M., Liebsch, M., Mehling, A., Netzlaff, F., Niedorf, F., 
Rübbelke, M.K., Schäfer, U., Schmidt, E., Schreiber, S., Schröder, K.-R., Spielmann, H. and Vuia1, A. (2006). 
 50
Reconstructed Human Epidermis for Skin Absorption Testing: Results of the German Prevalidation Study. 
ATLA 34, 283-294. 
Schäfer-Korting, M., Bock, U., Diembeck, W., Düsing, H.J., Gamer, A., Haltner-Ukomadu, E., 
Hoffmann, C., Kaca, M., Kamp, H., Kersen, S., Kietzmann, M., Korting, H.C., Krächter, H.U., Lehr, 
C.M., Liebsch, M., Mehling, A., Müller-Goymann, C., Netzlaff, F., Niedorf, F., Rübbelke, M.K., 
Schäfer, U., Schmidt, E., Schreiber, S., Spielmann, H., Vuia, A. & Weimer, M. (2008) The use of 
reconstructed human epidermis for skin absorption testing: Results of the validation study. ATLA 36, 161-187. 
Scott, L., Eskes, C., Hoffman, S., Adriaens, E., Alepee, N., Bufo, M., Clothier, R., Facchini, D., Faller, C., 
Guest, R., Hamernik, K., Harbell, J., Hartung, T., Kamp, H., Le Varlet, B., Meloni, M., Mcnamee, P., Osborn, 
R., Pape, W., Pfannenbecker, U., Prinsen, M., Seaman, C., Spielmann H., Stokes, W., Trouba, K., Vassallo, M., 
Van den Berghe, C., Van Goethem, F., Vinardell, P. & Zuang, V. (2010). Bottom-up and Top-down Approach: 
Eye Irritation Testing Strategy to Reduce and Replace in vivo studies. Toxicology In Vitro 24, 1-10. 
Sohn, K., Ju, J.H., Lee, J.P., Kim, J.H., Lim, C.H., Hong, S.K., Kwon, T.R., Chan, M., Yoon, H.S., Kim, D.S. & 
Park, K.L. (2009) Alternative methods for phototoxicity testing using reconstructed human skin models. Altex 
26: Special Issue, 136. 
Spielmann, H., Hoffmann, S., Liebsch, M.,  Botham, P., Fentem, J., Eskes, C., Roguet, R., Cotovió, J., Cole, T., 
Worth, A., Heylings, J., Jones, P., Robles, C., Kandárová, H., Gamer, A., Remmele, M., Curren, R., Raabe, H., 
Cockshott, A., Gerner, I. & Zuang, V. (2007). The ECVAM International Validation Study on In Vitro Tests for 
Acute Skin Irritation: Report on the Validity of the EPISKIN and EpiDerm Assays and on the Skin Integrity 
Function Test. ATLA 35, 559-601. 
Stummann, T.C., Beilmann, M., Duker, G., Dumotier, B., Fredriksson, J.M., Jones, R.L., Hasiwa, M., Kang, 
Y.J., Mandenius, C.F., Meyer, T., Minotti, G., Valentin, Y.J., Zünkler, B.J. & Bremer, S. (2009). Report and 
recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-
induced Cardiotoxicity. Cardiovasc Toxicol. 3, 107-125. 
Tsakovska, I., Gallegos, A., Netzeva, T., Pavan, M. & Worth, A.P. (2007). Evaluation of SARs for the 
prediction of eye irritation/corrosion potential – structural inclusion rules in the BfR decision support system. 
SAR & QSAR in Environmental Research 18, 221-235.  
Tsakovska, I,, Lessigiarska, I,, Netzeva, T. & Worth, A.P. (2008). A Mini Review of Mammalian Toxicity 
(Q)SAR Models. QSAR & Combinatorial Science 27, 41-48. 
Van der Sandt, J.J.M., Maas, W.J.M., van Burgsteden, J.A., Sartorelli, P., Montomoli, L., Kenyon, S., Robinson, 
E., Dick, I., Nilsen, J., Schaller, K.-H., Korinth, G., Cage, S., Wilkinson, S.C. & Williams Faith, M. (2004). In 
vitro predictions of skin absorption of caffeine, testosterone and benzoic acid: a multi-centre comparison study. 
Regulatory Toxicology and Pharmacology 39, 271-281. 
van Leeuwen, C.J., Patlewicz, G.Y. & Worth, A.P. (2007). Intelligent Testing Strategies, in Risk Assessment of 
Chemicals. An Introduction. 2nd Edition. CJ van Leeuwen & TG Vermeire (Eds). Springer, Heidelberg, 
Germany, pp. 467-509.  
Verma, K., Agrawal, N., Misra, R.B., Farooq, M. & Hans, R. (2008). Phototoxicity assessment of drugs and 
cosmetic products using E. Coli. Toxicology in Vitro, 22 (1), 249-253. 
Worth, A.P. & Patlewicz, G. (2007). A Compendium of Case Studies that helped to shape the REACH 
Guidance on Chemical Categories and Read-Across. (Eds). European Commission report EUR 22481 EN. 
European Commission-Joint Research Centre, Ispra, Italy. Available  from: 
http://ecb.jrc.ec.europa.eu/qsar/publications/. Accessed 12/01/2010 
Worth, A.P. (2010). The role of QSAR methodology in the regulatory assessment of chemicals, in Recent 
Advances in QSAR Studies: Methods and Applications. MTD Cronin, J Leszczynski & T Puzyn (Eds.). 
Springer, Heidelberg, Germany. In press. 
 51
Zuang, V., Barroso, J., Cole, T., Ceridono, M. & Eskes, C. (2010) ECVAM Bottom-Up/Top-Down Testing 
approach: testing strategy to reduce/replace the Draize eye test and validation/regulatory acceptance of in vitro 
assays: current status. Proceedings of the 7th World Congress on Alternatives and Animal Use in the Life 
Sciences. Rome, Italy. ALTEX. In press. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52
European Commission 
 
EUR 24413 EN– Joint Research Centre – Institute for Health and Consumer Protection 
Title: ECVAM Technical Report on the Status of Alternative Methods for Cosmetics Testing 
(2008-2009). A report prepared in the framework of Directive 2003/15/EC (7th Amendment to the Cosmetics 
Directive) 
Author(s): Valérie Zuang, João Barroso, Susanne Bremer, Silvia Casati, Mara Ceridono, Sandra Coecke, 
Raffaella Corvi, Chantra Eskes, Agnieszka Kinsner, Cristian Pellizzer, Pilar Prieto, Andrew Worth and Joachim 
Kreysa 
Luxembourg: Publications Office of the European Union 
2010–52 pp. – 21 x 29,5 cm 
EUR – Scientific and Technical Research series – ISSN 1018-5593 
ISBN 978-92-79-16021-9 
DOI 10.2788/99101 
 
Abstract 
The ECVAM technical report presents the progress made in the development and validation of alternative 
methods for the human health effects relevant to the Cosmetics Directive. It provides an update on the activities 
described by ECVAM in 2005, 2006 and 2007. 
 
The report intends to present the latest scientific and technical developments in the field during 2008-2009. As 
required by Directive 2003/15/EC, the seventh amendment to Directive 76/768/EEC, developments in 
refinement and reduction methods are also described (EU, 2003). 
 
Most successes in the development of alternative methods are in acute local toxicity and short-term testing, 
such as e.g. skin and eye irritation/corrosion, phototoxicity and skin penetration The test methods consuming a 
high number of animals, however, are in long-term testing and systemic toxicity, such as e.g. reproductive 
toxicity and repeated dose toxicity. In these complex fields, several research initiatives are ongoing. However 
full replacement approaches are still lacking. 
 
 53
How to obtain EU publications 
 
Our priced publications are available from EU Bookshop (http://bookshop.europa.eu), where you can place 
an order with the sales agent of your choice. 
 
The Publications Office has a worldwide network of sales agents. You can obtain their contact details by 
sending a fax to (352) 29 29-42758. 
 
 
 54
The mission of the JRC is to provide customer-driven scientific and technical support 
for the conception, development, implementation and monitoring of EU policies. As a 
service of the European Commission, the JRC functions as a reference centre of 
science and technology for the Union. Close to the policy-making process, it serves 
the common interest of the Member States, while being independent of special 
interests, whether private or national. 
 
 
 
LB
-N
A
-24413-EN
-C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                       
                                                                                                                                  
